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ABSTRACT 
 
Rebecca Dragomani: No Child Left Behind: A Quality Improvement Clinical Implementation to Improve 
Treatment Outcomes, Quality of Care, and Quality of Life and for Children with Attention Deficit 
Hyperactivity Disorder at a Rural Primary Care Practice  
(Under the direction of Victoria Soltis-Jarrett) 
 
Background and Rationale: Children with attention deficit hyperactivity disorder (ADHD) 
consistently report lower quality of life than their neurotypical peers and are at substantially increased risk 
for development of a comorbid psychiatric disorder. Fewer than half are prescribed an initial medication 
that is both efficacious and tolerable. Pharmacogenomic testing identifies medications likely to cause side 
effects and is available for use in routine clinical practice, although its effects on the quality of life among 
children who are prescribed medication for ADHD has not yet been evaluated.  
 Problem: Genetic differences contribute to the wide variability of response to ADHD 
medications but are not considered in treatment decisions. Quality of life, which correlates with the 
development of psychiatric comorbidities, is rarely assessed.  
 Purpose:  The project aimed to improve the quality of care, treatment outcomes, and quality of 
life for school-aged children with ADHD at a primary care practice by implementing a comprehensive 
bundle of practice changes that individualize treatment of ADHD.  
Methodology: The impact of routine pharmacogenomic testing on the incidence of ADHD 
medication side effects and change in behavioral symptoms was evaluated using retrospective chart 
review data.  A convenience sample of 52 charts included 26 charts of patients who received 
pharmacogenomic testing (PGT) prior to being prescribed medication for ADHD and a second group of 
26 patients who did not receive testing (No PGT). Quality of life was measured using cross-sectional data  
from 40 KINDL Quality-of-Life Questionnaires (parent-respondent).  Quality of care was assessed 
through parent interviews.  
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Results:  All QI initiatives were fully adopted. Pharmacogenomic testing was associated with 
fewer moderate and severe ADHD medication side effects (PGT 1.1 vs. No PGT 2.4) and greater 
differences in behavioral symptom scores (PGT -32 vs. NPGT -15.8). Mean quality-of-life scores of 
children with ADHD (PGT - 80.3, No PGT - 75.5, History Unknown 71.2) were higher than the 
benchmark averages.  
Conclusion: The results support the continued use of pharmacogenomic testing prior to 
prescribing medication to children for ADHD, use of standardized assessments of response, and quality-
of-life assessments to identify children at higher risk for the development of comorbid psychiatric 
disorders.
 v 
 
ACKNOWLEDGEMENTS 
 
          To everyone who made this project possible, especially my mentors:  Dr. Victoria Soltis-Jarrett, 
PhD, RN, PMHCNS/NP-BC, who inspired me to become a psychiatric nurse practitioner and whose 
wisdom shaped and guided this project from inception to its final form; Dr. Patrick Godwin, MD, who 
implements ideal care in actual care, for his insightful contributions to the design of this project; Tabatha 
Horner, FNP-BC, whom I mirrored and echoed as I learned the role of a family nurse practitioner and 
whose championship of this project engineered the means to overcoming implementation challenges; Dr. 
Helen Gordon, PhD, CNM, who encouraged me to think outside the box and has been a continuing source 
of both aid and inspiration; Dr. Amanda Davis, DNP, PNP-C, for her assistance with the manuscript and 
support through the doctoral process; Dr. Brian Wall, MD, who teaches me to talk so that children listen, 
and to listen so that children know that they are heard; and my dad, Dr. Charles “Tony” Russell, PhD, 
who inspires me to make my life meaningful through meaningful service to others and provides enduring 
support.  Thank you all so much.  I will remain forever grateful. 
 
 vi 
 
TABLE OF CONTENTS 
LIST OF TABLES ...........................................................................................................................x 
LIST OF FIGURES ....................................................................................................................... xi 
LIST OF ABBREVIATIONS ....................................................................................................... xii 
CHAPTER 1: INTRODUCTION ....................................................................................................1  
Background and Significance ..............................................................................................1 
Problems with Standard Treatment ......................................................................................3 
Risks of Not Treating ADHD ..............................................................................................3 
Social Context ......................................................................................................................5 
Problem Statement ...............................................................................................................6 
Local Problem ......................................................................................................................6 
Pharmacogenomic Testing ...................................................................................................7 
Significance to Healthcare ...................................................................................................8 
Purpose .................................................................................................................................9 
Clinical Question .................................................................................................................9 
CHAPTER 2: LITERATURE REVIEW .......................................................................................10 
Literature Search ................................................................................................................10 
Prevalence ..........................................................................................................................10 
Advances in Understanding of ADHD ..............................................................................11 
Pharmacogenomic Testing .................................................................................................12 
 vii 
 
Validity ..................................................................................................................12 
Clinical Utility .......................................................................................................13 
Generalizability of Depression Studies ..............................................................................13 
Known Risks ......................................................................................................................14 
Quality of Life....................................................................................................................14 
Gaps in the Current Literature ...........................................................................................15 
CHAPTER 3: CONCEPTUAL AND THEORETICAL FRAMEWORK.....................................17 
Resilience Theory ..............................................................................................................17 
CHAPTER 4: METHODS .............................................................................................................21 
Setting ................................................................................................................................21 
Study Participants ..............................................................................................................22 
Inclusion Criteria ...................................................................................................22 
Exclusion Criteria ..................................................................................................22 
Sample Size ............................................................................................................22 
Instruments .........................................................................................................................23 
Design ................................................................................................................................24 
Data Analysis .....................................................................................................................29 
Ethical Considerations .......................................................................................................29 
Implementation and Evaluation Procedures ......................................................................29 
Phase 1: Implementation of Vanderbilt Follow-up Forms ................................................30 
Implementation Procedure .....................................................................................30 
Phase 2: Implementation of Routine Pharmacogenomic Testing ......................................31 
Implementation Procedure .....................................................................................31 
 viii 
 
Modifications to Side Effect and Behavioral Symptom Scoring ...........................31 
Evaluation Procedure .............................................................................................32 
Implementation of the Quality-of-Life Questionnaire .......................................................32 
Implementation Procedure .....................................................................................32 
Implementation of the Quality-of-Life Survey ..................................................................33 
Survey Evaluation Procedure .................................................................................33 
Evaluation of the Quality of Care ......................................................................................34 
CHAPTER 5: RESULTS ...............................................................................................................35 
Evaluation of Documentation Compliance ........................................................................35 
Results of the Pharmacogenomic Testing Evaluation .......................................................36 
Demographic Data .................................................................................................36 
Medication Side Effects .........................................................................................37 
Behavior Change ....................................................................................................37 
Results of Quality-of-Life Assessments ............................................................................38 
Demographics ........................................................................................................38 
Survey Results .......................................................................................................38 
Trends in Responses ..............................................................................................39 
Study Participants Compared to Benchmark Averages .........................................39 
Evaluation of Quality of Care ............................................................................................40 
Client Feedback .....................................................................................................40 
CHAPTER 6: DISCUSSION .........................................................................................................42 
Attributes............................................................................................................................42 
Small-Scale Quality Improvement Evaluations .....................................................43 
 ix 
 
Limitations .........................................................................................................................44 
Recommendations for Future Studies ................................................................................44 
CHAPTER 7: CONCLUSION ......................................................................................................46 
APPENDIX A: DSM-5 DIAGNOSTIC CRITERIA FOR ADHD................................................48 
APPENDIX B: ADHD QI IMPLEMENTATION PROTOCOL ..................................................50 
APPENDIX C: NICHQ VANDERBILT ASSESSMENT SCALES ............................................52 
APPENDIX D: VANDERBILT FOLLOW-UP FORM – PARENT RESPONDENT .................57 
APPENDIX E: KINDL QUALITY-OF-LIFE QUESTIONNAIRE ........................................................... 61 
APPENDIX F: KINDL COLLABORATION LETTER ...............................................................65 
REFERENCES ..............................................................................................................................66 
 x 
 
LIST OF TABLES 
 
Table 1: QI Evaluation:  Alignment of Project Purpose, Outcome Measures,  
Methods, & Analysis ...................................................................................................................... 26 
 
Table 2: Evaluation of the Effects of Pharmacogenomic Testing on Changes in  
Behavioral Symptoms and Incidence of Moderate or Severe ADHD  
Medication Side Effects for Children Receiving and Not Receiving  
Pharmacogenomic Testing.............................................................................................................. 37 
 
Table 3: Results of the KINDL Quality-of-Life Questionnaire Survey of  
Study Participants ........................................................................................................................... 38 
 
Table 4: Comparison of Benchmark Quality-of-Life Scores Using the KINDL  
 Questionnaire:  Children without Chronic Health Disorders (BELLA) vs.  
Children with ADHD (OBSEER)  .................................................................................................. 40 
 
  
 xi 
 
LIST OF FIGURES 
Figure 1: Formula for Calculating KINDL Quality-of-Life Scores .......................................................... 34 
 
 xii 
 
LIST OF ABBREVIATIONS 
 
AAP American Academy of Pediatrics 
ADHD Attention Deficit Hyperactivity Disorder 
 
ANOVA Analysis of Variance 
 
APA American Psychiatric Association 
 
AVG Average (Mean) 
 
CDC Centers for Disease Control and Prevention 
 
CMS Center for Medicare and Medicaid Services 
 
DSM Diagnostic and Statistical Manual 
 
EMR Electronic medical record 
 
HRSA Health Resources and Services Administration  
IHI Institute for Healthcare Improvement 
IRB Institutional Review Board 
 
JACHO  Joint Commission:  Accreditation, Health Care, Certification  
 
KINDL KINDL Quality-of-Life Questionnaire 
 
PGT Pharmacogenomic testing 
 
Pt. Patient 
 
N Number 
 
NICHQ National Institute for Children’s Healthcare Quality 
 
NIMH National Institute of Mental Health 
 
NS Not significant 
 
QI Quality Improvement 
 
QoL Quality of Life 
 
RCT Randomized Clinical Trial 
U.S. United States of America 
 xiii 
 
VA U. S. Department of Veterans Affairs 
VS. Versus 
WA  Washington 
 1 
 
 
 
 
 
CHAPTER 1:  INTRODUCTION 
 
Background and Significance 
              By the time they graduate from high school, nearly one out of every five boys and one of every 
eleven girls in the United States is diagnosed with attention deficit hyperactivity disorder (ADHD) 
(Centers for Disease Control and Prevention [CDC], 2011).  Although ADHD is one of the most 
frequently diagnosed disorders in children (CDC, 2017), it remains one of the most poorly understood, 
and poorly managed, chronic health disorders worldwide (Danckaerts et al., 2010).  The guidelines for the 
evaluation and management of ADHD among school-aged children, published by the American Academy 
of Pediatrics (AAP) in 2011, recommend stimulant medication, preferably with behavioral therapy, as 
first-line treatment for school-aged children (Perrin et al., 2011).   Yet, only 41% of children will be 
prescribed a medication that is both efficacious and tolerable at their initial visit (American Academy of 
Child and Adolescent Psychiatry [AACAP], 2007).  Dosing also poses challenges.  Because of significant 
genetic variability in response, ADHD medications are not dosed by weight (Wall et al., 2012).  The 
landmark National Institute of Mental Health (NIMH) Multimodal Treatment Study of Children with 
ADHD (MTA) (1999) trial found that even with meticulous titration every three days, 64% of children 
with ADHD suffered medication side effects.  The most frequently reported side effects of ADHD 
medications are: sleep disturbance, decreased appetite, weight loss, nausea, abdominal pain, anxiety, tics, 
headaches, rebound irritability, and flattened affect (NIMH MTA, 1999; AAP 2011).  Current literature 
indicates that 48% of children who take ADHD medications report side effects, and 21% describe their 
ADHD medication side effects as “very bothersome” (Cascade, Kalali, & Wigal, 2010). 
     Medical and scientific research has advanced our understanding of the etiology, evaluation, and 
treatment of ADHD over the past seven years, but little of this knowledge has been translated to routine 
clinical practice.  Many of the challenges in the management of ADHD stem from genetic differences 
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among individuals, which contribute to the wide variability of response to ADHD medications and to the 
unpredictability of individual dosing requirements (Chou et al., 2000).  ADHD is inherently complex, 
with a multifactorial etiology, different foci, (Kessler, 2017) multiple subtypes and presentations (Amen, 
2017), and its course is influenced by socioeconomic, environmental, individual, and genetic factors 
(Chacko, Kofler, & Jarrett, 2014).  To effectively improve outcomes of children with ADHD, treatment 
needs to be personalized to consider individual genetic factors that affect metabolism of medications 
(Barkley, 2006; Faraone & Kunwar, 2018) and patients’ quality of life during treatment (Becker et al., 
2011).  Practical strategies to individualize treatment to improve the efficacy, tolerability, and quality of 
life for children with ADHD need to be implemented and systematically evaluated in clinical settings to 
align clinical practice with current knowledge of ADHD.  
ADHD is a childhood-onset, chronic neurodevelopmental disorder, causing a sustained inability 
to focus, as well as impulsive and/or hyperactive behavior in two or more settings (Puper-Quakil, Ramoz, 
Lepagnolbestel, Gorwood, & Simonneau, 2011).  The diagnostic criteria for ADHD are described in the 
Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) (see Appendix A). The 
Vanderbilt Attention-deficit/Hyperactivity Rating Scale – Parent and Teacher Assessment forms 
(National Institute for Children’s Health Quality [NICHQ], 2002) are among the most frequently used 
diagnostic tools, since the questions on the Vanderbilt Rating Scale describe behaviors that correspond to 
the DSM-5 diagnostic criteria for ADHD and establish their presence or absence in two or more settings 
(American Psychiatric Association [APA], 2013).  Additional questions screen for other potential 
disorders that may cause the patient’s symptoms, and the scoring guidelines help providers to determine 
whether the behaviors on the scale meet diagnostic criteria for ADHD.  
The American Academy of Pediatrics (AAP) (2011) recommends prescribing stimulant 
medication and/or behavioral therapy, with a combination of medication and behavioral therapy as the 
preferred treatment.  Unfortunately, the limited number of pediatric behavioral therapists, families’ 
inability to absorb out-of-pocket expenses, and parents’ difficulty taking time off work preclude 
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behavioral therapy as a viable treatment option for many families.  The goal of treatment of ADHD 
established by the AAP (2011) is remission of ADHD behavioral symptoms, which the AAP defined as a 
50% or greater reduction of symptoms and elimination of impairment (Perrin et al., 2011).  Response to 
treatment, with respect to frequency of symptoms, extent of impairment, and severity of medication side 
effects, is assessed by the children’s parents, who report their observations to their children’s healthcare 
providers.  Unless the physical assessments are notably different or children are suffering ADHD 
medication side effects at the time of their follow-up visits, the children’s experiences of treatment may 
not be a significant factor in treatment planning. 
Problems with Standard Treatment 
Pharmacological treatment of ADHD is an imprecise process that may require a series of 
medication trials before treatment is therapeutic.  The ADHD information webpage on the CDC website 
(2017) cautions parents that children respond differently and the medication that works for one child may 
not work for another child.  The CDC advises parents to have patience, as their providers may need to try 
several medications and different dosages before finding one that works for their child.  The American 
Academy of Child and Adolescent Psychiatry (AACAP) (2011) ADHD Treatment Algorithm presumes 
as facts that only 41% of children will respond well to the first stimulant medication prescribed for 
ADHD; another 44% of children will respond better to another stimulant in a different class.  The 
remaining 15% will not respond to a stimulant and should be prescribed a non-stimulant such as:  
amoxetine, guanfacine XR, or clonidine, in that order (AAP, 2011).  Although eventually 75-80% of 
children with ADHD will tolerate and benefit from medication for ADHD, noncompliance rates are high 
(AAP, 2011).  Intolerable medication side effects are the most frequently cited reason for discontinuation 
of ADHD pharmacotherapy (Cormier, 2012; Demidovich, Kolko, Bukstein, & Hart, 2011; Sitholey, 
Agarwal, & Chamoli, 2011; Wietecha et al., 2013). 
Risks of Not Treating ADHD 
          Undiagnosed and untreated ADHD substantially increases a child’s risk for numerous undesirable 
 4 
 
behavioral, health, and social outcomes over the lifespan (CDC, 2015).  Almost half of children with 
ADHD are suspended from school once, and 80 to 90% are significantly behind in school by fourth grade 
(Johnson-Verwayne, 2015). Dalsgaard et al. (2015) found that, after adjusting for confounders, 
individuals who were diagnosed with ADHD at or after the age of 18 were four times as likely to die 
prematurely, which is consistent with the AAP (2011) report that children with ADHD are twice as likely 
as their neurotypical peers to die in childhood from unintentional pedestrian injuries.  Epidemiological 
studies indicate that 75% of children with ADHD will develop a co-morbid psychiatric condition in their 
lifetimes (Barkley, 2006; Faraone & Kunwar, 2018).  
Fortunately, ADHD is amenable to treatment.  Adherence to pharmacologic therapy is associated 
with significant reduction in childhood accidents, motor vehicle accidents, and all substance abuse 
disorders among children and adolescents with ADHD (Biederman, 2003).  The risk of dying before the 
age of 18 years in an unintentional pedestrian accident was reduced by 50-80% when children with 
ADHD consistently took stimulant medication to treat ADHD (AAP, 2011).  Dalsgaard et al. (2015) 
found that diagnosis of ADHD by age six decreased the risk of premature death by 50%.  Children 
diagnosed with ADHD who took medication achieved math scores that averaged 2.9 points higher and 
reading scores that were 5.4 points higher than children with ADHD who did not take medication 
(Scheffler et al., 2009).  These scores represent learning gains of approximately 20% of a school year in 
math and 33% of a school year in reading (Scheffler et al., 2009).  
Although ADHD is a chronic health disorder, it is not treated as the classic chronic health 
disorders such as diabetes, hypertension, or asthma. Healthcare providers do not typically assess 
children’s risk of developing sequelae to ADHD, consider the impact of treatment on quality of life, or 
initiate care pathways aimed at reducing risk factors for known comorbidities.  Treatment of ADHD in 
school-aged children requires long-term adherence to pharmacotherapies to reduce impairment, the 
development of psychiatric comorbidities (NIMH, 2015), and numerous other undesirable sequelae 
(Barkley, 2006; Dalsgaard et al., 2015; Faraone & Kunwar, 2018).   
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Social Context  
Widespread public suspicion that providers are over-diagnosing ADHD and medicating children 
draws attention from the mainstream media with little rebuttal from the medical community.  Social 
critics credit passage of the “No Child Left Behind Act” in 2002, which implemented national 
performance-based educational funding, as the greatest contributor to the soaring rates of ADHD 
diagnoses among school-aged children in the United States.  Dr. Hinshaw and his colleagues at the 
University of California (2011) examined data from the National Survey of Children’s Health from 2003-
2007 and found that in the 20 states that did not have performance-based educational funding prior to 
2002, diagnosis of ADHD increased 56% among children whose median household incomes were within 
200% of the federal poverty level, compared to 3% in middle-class children, and 19% in children with the 
same socioeconomic status in other states (Novotney, 2014).  
Performance-based educational funding encourages schools to ensure that students perform well 
on standardized tests.  The scores of children diagnosed with ADHD are not counted in the school 
averages.  Further, since ADHD is classified as a learning disability, schools with large populations of 
children with ADHD receive additional funding for accommodations such as smaller classes to provide 
more individualized attention.  Dr. Hinshaw and his colleagues (2011) point out that children in North 
Carolina, one of the first states to implement performance-based educational funding, are five times more 
likely to be diagnosed with ADHD than children in California, where performance-based policy was more 
recently implemented (Novotney, 2014).   
Health care providers in North Carolina may rightfully insist that they are following the practice 
guidelines (AAP, 2011), that multiple cultural factors account for the discrepancies in diagnosis rates, and 
point out that North Carolina’s children are also more likely to be vaccinated (CDC, 2014), yet the air is 
not entirely cleared.  Whatever truths underlie the geographically disproportionate rates of diagnoses, the 
media draws concerned attention to our system of care for children with ADHD, which is plagued with 
inadequacies.  Attempting to address the inadequacies of the system using the same practices that created 
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the dysfunction only sustains it.  To ensure that care for children with ADHD is truly patient-centered and 
health-promoting, new practice standards must be implemented, starting with standardization to ensure 
that consistent, comprehensive assessments are performed every visit and that patient-parent goals and 
patient-reported outcomes are included in treatment planning (Frankel, Haraden, Federico, & Lenoci-
Edwards, 2017).   
Problem Statement 
Children with ADHD are at significant risk for developing co-morbid psychiatric disorders by 
early adulthood (Barkley, 2006).  The literature consistently affirms that psychosocial resilience in 
childhood is one of the strongest predictors of good mental health (Perese, 2012). Wide variability in 
response to ADHD medications creates treatment challenges for healthcare providers, and insufficient 
information is available to assist providers with selection of the most effective medication and dose for 
individual patients.  The trial-and-error method of treating ADHD results in high rates of ADHD 
medication side effects, inefficacy, and poor quality of life (Boorady, 2015).  Treatment response 
assessments centered on discussions of the child’s behavior may decrease self-esteem, hence decrease 
resilience and increase the already substantial risk for development of psychiatric behavioral health 
comorbidities.  Healthcare providers are challenged to design and deliver treatment that alleviates an 
individual’s symptoms of ADHD, improves quality of life, and promotes resilience. 
Local Problem 
While successful treatment of ADHD increases a child’s resilience, persistent side effects of 
ADHD medication can decrease resilience by increasing anxiety or causing over-focused fixation, which 
inhibits social-emotional engagement and development.  At the practice level, the gap between desired 
outcomes and actual outcomes is consistent with the national statistics that describe a wide variability of 
responses to standard treatments for ADHD among school-aged children.  While most children with 
ADHD will eventually achieve symptom remission with pharmacologic treatment and report only mild 
medication side effects, paradoxical reactions, in which the medications exacerbate problems, are not 
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uncommon.  Further, a significant number of children exhibit a “partial response” after multiple dosing 
adjustments and medication changes.  Their parents report that behavioral symptoms and performance 
have improved significantly, removing threats of school suspension and failing grades, but symptomatic 
behaviors and medication side effects persist.  Children with a partial response often present as anxious, 
agitated, or hyper-focused, with flattened affect, and parents will typically report moderate appetite loss, 
irritability, and insomnia.  According to the AAP guidelines (2011), treatment may be considered 
successful if the patient’s symptoms are reduced and he or she experiences no impairment. Yet, a 
flattened affect, anxiety, and decreased social engagement (NIMH MTA, 1999), when experienced nearly 
every day, may erode a child’s sense of self-efficacy, stunt social-emotional development, and ultimately 
decrease a child’s psychosocial resilience.  In summary, these subtle side effects ultimately undermine the 
child’s best defense against co-morbid disorders (Perese, 2012).   
The Institute for Healthcare Improvement (IHI) recommends measuring current outcomes and 
establishing baseline values prior to implementing a change in treatment (Frankel et al., 2017). At the 
study site for this project, documentation in the patient charts regarding behavioral symptom responses 
and ADHD medication side effects were frequently vague.  Use of the Vanderbilt Follow-up forms was 
inconsistent.  An initial chart review revealed that as of November 1, 2017, only 49% of the patient charts 
in the target population contained both a Vanderbilt Rating Scales and Vanderbilt Follow-up form.  When 
parents were called to schedule a follow-up appointment, 9 of the 57 stated that the child no longer took 
medication for ADHD.  
Pharmacogenomic Testing 
Pharmacogenomic tests may help healthcare providers select the most tolerable and efficacious 
ADHD medications for patients based on their individual genetic profiles (Assurex Health, 2012).  The 
tests analyze genes involved in the metabolism and pharmacokinetics of ADHD medications by 
identifying genotypes and analyzing variants that affect a patient’s ability to tolerate or respond as 
expected to medications (Assurex Health, 2012; Chou et al., 2000; de Leon, 2009). Using a complex 
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software algorithm, the tests predict which medications are likely to be metabolized normally and which are 
likely to cause side effects, have reduced efficacy, or be metabolized at an exceptionally slow or rapid rate 
(Assurex Health, 2012; Washington State Health Care Authority [WA HCA], 2016). They analyze 52 
psychotropic medications, including almost all FDA-approved medications to treat ADHD (FDA, 2016), as 
well as medications to treat depression, anxiety, psychotic disorders, substance use disorder, and analgesics 
(Assurex Health, 2012; Hoak, 2016).  The test is administered by the patient’s healthcare provider, who 
collects DNA from the patient in the office using a buccal swab and ships it overnight to the lab.  Three 
days later, the provider receives a computerized report that can guide their treatment plan (Carlat, 2015).  
Pharmacogenomic tests for psychiatric medication prescribed to children are FDA-approved and 
available for routine use in primary care.  However, the literature indicates that the benefits of routine 
pharmacogenomic testing vary dramatically among different patient populations, despite being used as a 
decision support tool for treatment of the same diagnosis (Peterson, Dieperink, Ferguson, Anderson, & 
Hefland, 2016).  
Significance to Healthcare 
The quality improvement project discussed herein is unique in many respects.  It implements a 
comprehensive bundle of practice changes that together furnish providers with patient-specific 
information to inform treatment planning for children with ADHD.  Implementation of quality-of-life 
assessments inserts this issue, with its implications for psychosocial resilience, as a treatment outcome 
that has not previously been stipulated as part of the standard care for children with ADHD.  This fulfills 
the World Health Organization’s (2001) recommendation that treatment goals should include patient-
reported outcomes.  Further, it is the first quality improvement project to assess the effects of 
pharmacogenomic testing for psychotropic medications on quality of life.  Identifying and avoiding 
medications that are likely to be ineffective and/or cause side effects by identifying metabolic variants has 
improved treatment outcomes and the quality of care for children with ADHD (Tan-kam, Suthisisang, 
Limsila, Puangpetch, & Sukasem, 2013; Smith, Sharp, Manzardo, & Butler, 2015; Stein & McGough, 
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2008; Benitez et al., 2015).  Several studies indicate that pharmacogenomic testing provides a moderate 
cost benefit by avoiding costly adverse drug reactions (Celerian Group Services Administrators [CSG], 
2014; Singh, 2015; Winner et al., 2015).  Assessing quality of life allows providers to identify children at 
greatest risk and facilitate early intervention, which has proven effective at reducing the risk of 
developing psychiatric comorbidities (Tolan & Dodge, 2005).  Thus, this QI implementation promises to 
fulfill the “triple aim” of healthcare innovations:  improving health outcomes, enhancing experiences of 
care, and controlling or reducing costs of care (Berwick, Nolan, & Whittington, 2003).  
Purpose 
The purpose of this project is to improve the quality of life and treatment outcomes for school-
aged children with ADHD, and to reduce their risk of developing a psychiatric comorbidity, by designing, 
implementing, and evaluating a comprehensive bundle of practice changes: (a) standardized 
comprehensive and specific assessments to inform treatment planning, (b) routine pharmacogenomic 
testing to decrease side effects and improve efficacy, and (c) assessing quality of life as a goal of 
treatment.  
Clinical Question   
              Will the acquisition of more patient-specific information, through pharmacogenomic testing, 
standardized comprehensive follow-up forms, and quality-of-life assessments, improve treatment 
outcomes, experiences of care, and quality of life, for school-aged children with ADHD at the study site?
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CHAPTER 2:  LITERATURE REVIEW 
 
Literature Search 
A literature search was conducted using PubMed, CINAHL, Embase, the Cochrane Library, 
American Psychiatric Association, and JAMA evidence databases, UptoDate, and Google Scholar, using 
the terms (in CINAHL) “attention deficit hyperactivity disorder” OR “ADHD” AND “pharmacogenomic 
test” OR “gene testing” OR "combinatorial gene testing" OR "GeneSight" and using the terms “attention 
deficit hyperactivity disorder pharmacogenomic test” and “ADHD gene test” in the others.  Inclusion 
criteria included:  English language; published after January 1, 2005; covering children, adolescents, 
and/or adults; and full text available.  Exclusion criteria were:  articles published before 2005; language 
other than English; abstract only; covering infants and neonates.  The literature search was conducted to 
evaluate the best available evidence about the impact of pharmacogenomic testing on clinical outcomes of 
children with ADHD and included evidence of the effects of pharmacogenomic testing on outcomes of all 
psychiatric patients, as well as the impact of pharmacogenomic testing on healthcare costs for patients 
with psychiatric disorders.  A total of 106 articles was retrieved, which was reduced to 79 after duplicates 
were removed. After eliminating scientific articles about single genes and medications, 32 articles 
remained and were reviewed.   
The following sections will be presented and discussed as part of the literature review:   
(a) Prevalence; (b) Advances in Understanding of ADHD; (c) Pharmacogenomic Testing:  Validity;   
(d) Pharmacogenomic Testing:  Clinical Utility; (e) Generalizability of Depression Studies; (f) Known 
Risks; (g) Quality of Life; (h) Gaps in the Current Literature. 
Prevalence 
ADHD is one of the most frequently diagnosed pediatric disorders, and its prevalence continues 
to rise, increasing approximately 5% a year since 2006 (CDC, 2015; Holland & Riley, 2014).  Children 
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from households with incomes less than 200% of the federal poverty level are more than twice as likely to 
be diagnosed with ADHD as children from households with higher median household incomes.  
Prevalence of ADHD is higher in the South than in other geographic regions of the United States 
(Novotney, 2014).  School-aged boys (13.2%) are more than twice as likely as school-aged girls (5.6%) to 
be diagnosed with ADHD (CDC, 2015).  Numerous theories, including the earlier maturity of girls 
(Asherson, Manor, & Huss, 2014), gender-biased wording, and the predominance of externalized 
behaviors described in ADHD symptom rating scales (Mahone, 2012), have been proposed as 
explanations for the gender disparity of ADHD diagnoses, but the persistent profound difference in 
prevalence among genders remains an enigma (ADHD Institute, 2016).  Despite an increased prevalence 
of poverty among minority groups nationally, children from racial minority groups are less likely to be 
diagnosed with ADHD and less likely to be taking medication for ADHD (Morgan, Staff, Hillemeier, 
Farkas, & Maczuga, 2013).  Compared to Caucasian children, African American children are 31% less 
likely to be diagnosed with ADHD (95% confidence interval [CI]: 60%-76%), although the gap is closing 
(CDC, 2014).  Hispanic children are 50% less likely (95% CI: 34%-62%), and Asian and Native 
American children are 64% less likely (95% CI: 26%-61%) to be diagnosed with ADHD (Morgan et al., 
2013).  
Advances in Understanding of ADHD  
Since the AAP guidelines were published in 2011, science has advanced our understanding of 
ADHD.  In the DSM-5, the American Psychiatric Association (APA) reclassified ADHD as a 
neurodevelopmental disorder, as opposed to the DSM- IV classification as a disruptive behavioral 
disorder (APA, 2013).  The DSM-5 classification reflects a growing body of scientific evidence that 
indicates ADHD has specific pathophysiological and neurochemical etiologies (Puper-Quakil et al., 
2011). Brain mapping studies indicate that the pathogenesis of ADHD is widespread, and dysfunction 
occurs in multiple locations, including the frontal-parietal-cortical pathways, corpus callosum, anterior 
cingulate cortex, and cerebellum.  These areas are responsible for functions such as cognitive processing, 
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attention, motor control, executive functions, response inhibition, reward, and motivation (Uneri, Senses-
Dinc, & Goker, 2015).  
Brain-mapping analysis indicates that ADHD is not a uniform disorder.  While executive function 
deficits etiologically based in the frontal and pre-frontal cortex comprise the most common foci of ADHD 
(Kessler, 2017), there are at least seven subtypes of ADHD with varied functional deficits and 
presentations resulting from different etiologic foci. Treatment of the subtypes of ADHD is aimed at 
symptoms and does not always include a stimulant as first-line therapy (Amen, 2017).  The discovery of 
sub-types compels the use of more comprehensive assessments and follow-up to treat appropriately.  If a 
provider does not recognize a distinct subtype of ADHD, but assesses that the patient is failing to respond 
as expected to a medication that pharmacogenomic test results indicate as metabolically compatible, the 
test results may—indeed, should— expedite a reassessment of the disorder and a change in the treatment 
plan rather than the usual practice of prescribing a stimulant medication from a different class (Perrin et 
al., 2011).   
Pharmacogenomic Testing 
Validity.  The validity of pharmacogenomic testing for ADHD medication selection is well-
supported by a large body of scientific evidence that identifies the functions of genetic variants involved in 
the metabolism of psychotropic medications and allows testing to accurately match these genotypes with 
metabolic phenotypes (Bonvincini et al., 2016; Benitez, Jablonski, Allen, & Winner, 2015; Contini et al., 
2013).  Numerous studies confirm that pharmacogenomic markers accurately predict responses to the most 
frequently prescribed ADHD medications (Mrazek, 2009; Contini et al., 2013; Kim et al., 2013). More than 
6,700 articles in the Pub Med database describe studies of gene variants related to the metabolism of ADHD 
medications.  All pharmacogenomic tests for psychotropic medications identify variants of genes that encode 
the cytochrome (CYP) enzymes, which metabolize 70% of all psychotropic medications, including 
medications prescribed to treat ADHD:  methylphenidate (Patel & Barzman, 2013; Contini et al., 2013) and 
amoxetine (Durham, 2014; Smith et al., 2014).   
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Clinical Utility.  Evidence of the impact of pharmacogenomic testing for medication selection in 
treating ADHD is derived from smaller, open-label studies (Howland et al., 2014).  Brennan et al. (2015) 
conducted a naturalistic clinical trial of the utility of pharmacogenomic testing for various psychiatric 
medications, including some used for treating ADHD, among 85 primary care patients.  They concluded 
that all patients who received pharmacogenomic testing exhibited clinically significant improvement at 
three months. Stein & McGough (2008) reviewed several studies and concluded that pharmacogenomic 
testing for ADHD medication selection improves clinical outcomes.  Three peer-reviewed case studies 
validate the ability of pharmacogenomic tests to correctly predict responses to ADHD medications.  Madan 
et al. (2015), Smith et al. (2015), and Tan-kam et al. (2013) report detailed case studies of children with 
severe, persistent ADHD symptoms.  The children achieved significant symptom remission following 
pharmacogenomic testing for medication selection, in conjunction with medication changes and dosage 
adjustments that corresponded with the test results.  
Generalizability of Depression Studies 
Many of the genotype-phenotype variants that predict responses to antidepressants, such as the 
dopamine transporter, noradrenergic transporter, and CYP2D6 enzymes, also predict responses to ADHD 
medications (Mrazek, 2010).  Clinical trials conducted by Breitenstein et al. in Germany (2014) and Singh 
(2015) in Canada indicate that pharmacogenomic-guided medication selection improved clinical 
outcomes for patients with a variety of psychiatric disorders.  In Singh’s (2015) double-blind randomized 
controlled trial (RCT) involving 148 patients, the pharmacogenomic-guided medication arm exhibited a 
2.52 times greater rate of symptom remission (p < 0.0001).  Pharmacogenomic testing is associated with 
significantly increased rates of remission from major depressive disorder in several RCTs (Altar et al., 2015; 
Mrazek, 2011; Hall-Flavin et al., 2011; Hall-Flavin et al., 2012; Winner et al., 2013).  A meta-analysis 
prepared for the Centers for Medicare and Medicaid Services (CMS) found that pharmacogenomic testing for 
antidepressants was associated with a 73% greater improvement in depressive symptoms (p = 0.004) (CSG, 
2014).  Among 165 patients with mood disorders enrolled in an open-label clinical trial at the Mayo 
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Clinic, the cohort who received medications based on pharmacogenomic testing results achieved a 
significantly higher rate of remission at eight weeks (40.1% vs. 19.5%, p < 0.001) (Hall-Flavin et al., 
2013).  When Winner (2013) offered pharmacogenomic testing to patients in the control group after the 
study period, he found that patients who had been taking antidepressants that the pharmacogenomic test 
later identified as having a high probability of gene-drug interactions had reported almost no 
improvement (0.8%) after 10 weeks of treatment.  These findings are consistent with findings by Altar et 
al. (2015), Breitenstein et al. (2014), and Brennan et al. (2015).   
Known Risks 
Systematic reviews compiling evidence of the effects of pharmacogenomic testing for psychotropic 
medications, including for ADHD, were performed by the U. S. Department of Veterans Affairs (VA) and 
the Washington State Health Care Authority (WA HCA), both of whom determined that pharmacogenomic 
testing posed no risk of harm (Peterson et al., 2016; WA HCA, 2016).  The only potential risk of using 
pharmacogenomic tests for psychotropic medication selection that was identified in the literature was the 
potential for insurance discrimination based on genetic profile (CSG, 2014).  Millennium Health and the 
CMS also determined that the risk of pharmacogenomic testing is negligible (CSG, 2014; Gupta, 
Hassainzada, & Del Tredici, 2016).  Altman (2011) asserts that the evidence of non-inferiority is sufficient 
for a clinical implementation trial of an intervention with no known risk.   
In summary, the true value of routine pharmacogenomic testing prior to prescribing medication 
for ADHD is not fully known.  However, the potential to positively affect outcomes, as documented above, 
coupled with no known risk of harm, provides a compelling reason to implement routine pharmacogenomic 
testing prior to prescribing medication to children with ADHD, with continuation and adoption contingent 
upon the evaluation finding clear evidence of benefit (Gillam & Siriwardena, 2014; Orr, 2003). 
Quality of Life 
The World Health Organization (WHO) International Classification of Functioning, Disability 
and Health (2001) recommended that health outcomes be considered in terms of the biopsychosocial 
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model and should include patient-reported health outcomes as goals of treatment.  Quality of life is a 
patient-reported outcome that is becoming increasingly prominent.  The WHO (2001) defines “quality of 
life” as an individual’s perception of their actual level of functionality compared to their perception of 
their optimal level of functionality with respect to physical and emotional health, family and social 
relationships, work, and self-concept (Danckaerts et al., 2010).  Research in the past decade has 
confirmed the positive association between quality of life and health outcomes in multiple populations 
and at all levels of care (Danckaerts et al., 2010; WHO, 2001).   
The quality of life reported by children with ADHD is persistently poor, sharing common themes 
of self-perceived social ineptitude, with consistently low scores in the areas of relationships with friends, 
family, and school and authority figures (Danckaerts et al., 2010).  Vagin (2017) reports that by 12 years 
of age, children with ADHD hear approximately 20,000 more negative messages than their neurotypical 
peers.  Parents of children with ADHD and children with ADHD report significantly poorer quality of life 
than children without chronic health disorders (Becker et al., 2011; Danckaerts et al., 2010).  Danckaerts 
and colleagues (2010) found that children with ADHD rated their own quality of life as poorer than many 
children with chronic physical health disorders.  The mean quality-of-life scores reported by children with 
ADHD were equivalent to the mean quality-of-life scores of children with cancer and cerebral palsy 
(Danckaerts et al., 2010).  Becker et al. (2011) found that taking medication to treat ADHD increased the 
patient-reported KINDL Quality-of-Life (QoL) scores from a mean of 63.8, reported by children with 
ADHD who did not take medication, to a mean of 67.2 for children with ADHD who took two doses of 
methylphenidate a day.  Taking methylphenidate for ADHD cut the gap between the quality-of-life scores 
of children with ADHD and children without ADHD by 50%.   
Gaps in the Current Literature 
Pharmacogenomic studies typically focus on treatment efficacy and cost-effectiveness, but so far 
as can be determined, this is the first quality improvement study to evaluate the effect of routine 
pharmacogenomic testing on patient experiences of care (incidence and severity of medication side 
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effects and quality of life) as primary outcomes.  Since pharmacogenomic testing reliably predicts 
abnormal metabolism and poor responses to medications but cannot determine the most appropriate 
choice of medication among tolerable choices, measuring the effect of these choices on patient 
experiences of side effects and quality of life is possibly the most appropriate outcome measure in terms 
of improving patient experiences of treatment (Benitez, Jablonski, Allen, & Winner, 2015). 
Although combinatorial pharmacogenomic tests have proven to be more beneficial than single-gene 
tests (Winner & Dechario, 2015), it is unknown whether the commercially available tests are all equally 
effective at identifying variants that affect metabolism of medications to treat ADHD or if some tests are 
superior with respect to predicting side effects, variations in metabolic rates, and/or inefficacy of medications 
that are approved to treat ADHD in children.  Each pharmacogenomic test is patented, therefore each uses 
unique algorithms, tests different genes, and includes different medications in its reports (Assurex Health, 
2012).  All pharmacogenomic tests include genes that code for the CYP enzymes that metabolize most 
medications (Durham, 2014). ADHD results are primarily based on the analysis of three genes:  CYP2D6, 
a gene that encodes enzymes that metabolize ADHD medication (NIH, 2015), COMT, a gene involved in 
the methylation and degradation of dopamine, epinephrine, and norepinephrine (Human Genes Database, 
2015), and ADRA2A, a gene that encodes receptors responsible for neurotransmitter release (NIH, 2015).  
Since studies report risk values in aggregate, without considering the variability among responses 
to ADHD treatment, the true value of the risk reduction among children who achieve ADHD symptom 
remission with a well-tolerated medication is unknown.  Unfortunately, no studies compare the quality of 
life of children who are treated effectively for ADHD with a tolerable medication, and the quality of life 
reported by their neurotypical peers (Dalsgaard et al., 2015; Biederman, 2003; Charach et al., 2011).  
Whether reducing ADHD medication side effects and expediting symptom remission significantly 
improves the quality of life for children with ADHD is also unknown.   
The following chapter presents an analysis of resilience theory, which provides the conceptual 
framework for this quality improvement project.   
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CHAPTER 3: CONCEPTUAL AND THEORETICAL FRAMEWORK 
 
Resilience Theory 
     The conceptual framework of this project is resilience theory. “Resilience” describes a quality 
that enables an individual not only to successfully navigate through adversity, significant hardship, and/or 
formidable challenges, but to transcend them and ultimately thrive (Perese, 2012).  Conceptually, 
resilience theory includes an antecedent of adversity and a consequence of a positive outcome (Fletcher & 
Sarkar, 2013).  The theory of resilience stipulates that the presence of protective attributes increases 
adaptive functionality and thereby increases one’s ability overcome challenges (Polk, 1997).  Although 
the factors contributing to resilience are numerous, all resilience models describe and predict outcomes 
based upon the balance between an individual’s “risk factors” and “protective factors” (Perese, 2012). 
Resilience theory describes and explains factors that affect a child’s psyche and predicts the effects of the 
factors, individually and combined, on mental health outcomes (Perese, 2012). The low level of 
psychosocial resilience among children with ADHD is considered both a cause and a consequence of 
ADHD (Regalla, Guilherme, Aguilera, Serra-Pinheiro, & Mattos, 2015).  Assessments of resilience are 
always subjective (Santos, 2016).  Nevertheless, resilience in childhood remains one of the strongest 
predictors of mental health in young adults (Perese, 2012; Masten, 2014), which makes resilience 
particularly relevant to healthcare providers who treat children with ADHD. 
The concept of resilience originated in the work of Werner, Bierman & French (1971) in the 
context of a longitudinal study about children on the Hawaiian island of Kauai.  Since World War II, 
resilience research has evolved primarily in the context of child development studies and the risk for the 
development of mental health disorders (Masten, 2014). Garmezy (1971), a psychologist, studied children 
at risk for the development of psychopathology and described the concept of resilience as “protective 
factors” that helped children to thrive despite the presence of significant risks.  The tests of his model 
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proved not only descriptive and explanatory, but also predictive of outcomes.  It was this formulation of 
the idea of resilience that evolved into resilience theory.  
The resilience model is comprised of three dynamic components, internal forces, external forces, 
and circumstances (Fleming & Ledogar, 2008; Perese, 2012), that cumulatively predict an individual’s 
ability to transcend specific challenges.  Enhancing hallmark qualities that contribute to resilience, such as 
self-discipline and self-esteem, increases one’s resiliency and supports healing and positive health 
outcomes (Perese, 2012).  Cultivating resilience in school-aged children who are at risk addresses the 
“internal forces” of a child’s adaptive mechanisms, such as emotional regulation, “external forces” such 
as recommendations for modification of the home and/or school environments, and “circumstances,” such 
as helping children to create narratives that allow them to make sense of their experiences and process 
aspects of their challenges (Perese, 2012; Muller, Ward, Winefield, Tsourtos, & Lawn, 2009).  Some 
factors of resilience among children are constant throughout the lifespan: strong parental attachments; 
warm, positive relationships with caregivers; and intelligence (Sapienza & Masten, 2011).  Resilience in 
school-aged children is primarily influenced by their relationships with their parents, but is also 
significantly influenced by the quality of their relationships with peers, scholastic engagement, and their 
self-concept with respect to social competence, self-efficacy, and capacity for self-regulation (Windle, 
Bennett, & Noyes, 2011).  Social and emotional skills programs for children (Tolan & Dodge, 2005) and 
positive parenting education programs (Dvorsky & Langberg, 2016) are early interventions that have 
increased children’s quality-of-life scores and reduced the likelihood of developing psychiatric disorders 
by early adulthood.  
Sapienza and Masten (2011) discourage “diagnosing” individuals as resilient.  Resilience is 
dynamic (Sapienza and Masten, 2011). It can only be gauged in the moment of a challenge as a ratio: 
demands of the situation vis-à-vis ability to adapt to or transcend the situation.  The scientific literature is 
consistent in its appraisals of the increased health and social risks conferred by a diagnosis of ADHD, 
while a growing number of people tout ADHD as an advantage rather than a handicap.  In an article 
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entitled, “ADHD: The Entrepreneur’s Superpower,” Archer (2017) reports that several successful 
entrepreneurs credit their ADHD for the traits that they view as fundamental to their success:  creativity, 
willingness to take risks, exceptional energy, and stamina.  Masten (2014) points to the “easy baby” and 
“fussy baby” theory, which long held that babies with easy temperaments were more adaptive and 
resilient.  Yet amidst the adversity of war and drought in Africa, it was the fussy babies who survived.  
Resilience theory is well-aligned with the overarching goals of primary care:  promotion of long-
term physical and mental health by increasing protective factors, as well as identifying and decreasing 
risk factors of individuals (Perese, 2012).  Resilience and perceived quality of life are reciprocal 
psychological states and consistently positively associated (Danckaerts et al., 2010). Although children’s 
risk for development of psychiatric/behavioral health disorders is typically predicted based on 
measurements of resilience rather than quality of life, the KINDL Quality-of-Life Questionnaire has been 
validated as a reliable instrument with which to measure psychosocial resilience in school-aged children 
(Danckaerts et al., 2010).  In this study, the KINDL Questionnaire was selected in conjunction with the 
practice owner and lead clinician at the clinical site. Approaching the factors of resilience by assessing 
quality of life empowers children to articulate their experiences of treatment and bolsters their self-esteem 
by indicating that their emotional responses to situations in their lives are important (Ravens-Sieber, 
Erhart, Willie, & Bullinger, 2008). 
In the context of the resilience model, improving outcomes of school-aged children with ADHD 
necessitated the incorporation of long-term treatment goals focused on improving quality of life. Quality 
of life among children with ADHD (Becker et al., 2011) was associated with social and emotional 
impairments as well as academic impairments that affected self-esteem. ADHD medication side effects 
can improve one area, such as academic competence, but cause even greater deficits in another, such as 
social engagement, that may be a bigger factor in resilience.  Improving children’s quality of life, and 
subsequently, increasing their resilience, began with improving the process of selecting the most 
efficacious and tolerable medications to reduce their symptoms of ADHD, which in turn indicated the   
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need for standardized assessment documentation.  Resilience theory thus led to quality-of-life 
assessments and the incorporation of patient-reported increase in quality of life as a goal of ADHD 
treatment in children. Chapter 4 describes the design, implementation and evaluation of this QI project.
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CHAPTER 4: METHODS 
The framework for the methodology of this quality improvement project was the Institute for 
Healthcare Improvement’s Model for Improvement, described in the IHI’s publication, “Framework for 
Safe, Reliable, Effective Care” (Frankel et al., 2017).  Quality improvement (QI) is defined as the 
“systematic and continuous actions that lead to measurable improvement in health care services and the 
health of targeted patient groups” (Health Resources and Services Administration [HRSA], 2011, p. 1). 
The IHI recommends using the model to guide QI implementation processes (Frankel et al., 2017).  It 
facilitates vetting of QI outcomes as well as the adaptations necessary to successfully integrate an 
improvement.  This chapter presents the methodology used to evaluate the study and its application to the 
project in the following sections: (a) Setting; (b) Study Participants; (c) Instruments;  
(d) Design; (e) Data Analysis; (f) Ethical Considerations; and (g) Implementation, Procedures, & 
Evaluation Methods. 
Setting 
The implementation site is a privately-owned family medicine practice located in a rural county 
of north-central North Carolina, designated as a critical healthcare shortage area (HRSA, 2017).   
Not a single pediatric psychiatrist or psychiatric mental health nurse practitioner who treats children 
practices in the county.  In 2016, providers at the clinical site (three physicians and two nurse 
practitioners) treated a total of 5,429 patients, 879 of whom were children aged 6 to 12 years, of which 
112 were children who were prescribed medication for ADHD.  
The practice serves as a clinical training site for the UNC at Chapel Hill Schools of Nursing and 
Medicine; in 2017, it was accredited as a primary care medical home by the Joint Commission for 
Accreditation, Health Care, & Certification (JACHO).  Continuous quality improvement (QI) and 
individualization of care plans are central values of the primary care medical home model (Patient-
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Centered Primary Care Collaborative, 2015).  Clinicians and providers at the site were inexperienced with 
quality improvement projects; however, the practice’s management team had undertaken structured 
quality improvement projects in the process of becoming a medical home and was familiar with some of 
the QI processes, which facilitated implementation of the data tracking and documentation improvements 
undertaken for this study.  A collegial, non-competitive work culture at the clinical site increased 
teamwork and cooperation, which supported the success of the change (Damschroder et al., 2009).   
Study Participants 
A total of 112 children, aged 6 to 12 years old, had been diagnosed with ADHD and/or prescribed 
medication for ADHD by providers at the practice within the previous year.   
   Inclusion Criteria.  Inclusion in the study necessitated that the child’s initial symptoms were 
documented on Vanderbilt Rating Scales – Parent and Teacher Assessment forms (see Appendix C) and 
filed in the electronic medical record (EMR).  The initial assessment needed to clearly indicate that the 
child met diagnostic criteria for ADHD in both the home and school settings.  At least one post-treatment 
assessment of the child’s symptoms needed to be documented on a Vanderbilt Follow-up form (see 
Appendix D) and available in the EMR. 
Exclusion Criteria.  Project exclusion criteria were incomplete documentation of the initial or 
follow-up ADHD visits: either the initial Vanderbilt Rating Scale – Parent and Teacher Assessment forms 
were missing or no Vanderbilt Follow-Up forms were filed in the patient’s chart. Patients were also 
excluded if the initial Vanderbilt Rating Scales were more than four years old. Patients diagnosed with 
medical or psychiatric comorbidities other than seasonal allergies, well-controlled asthma, or well-
controlled gastroesophageal reflux (GERD) were excluded from the sample. 
             Sample Size.  The chart review sample included two groups composed of 26 children each.  This 
satisfied the requirement that each group have a minimum of 25 patients to confer significance to a 
statistical test of variance.  The IHI (2012) recommends that QI evaluations include a minimum of 10 
patients, preferably more than 20, to ensure the results are not coincidental.  
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Instruments 
The following instruments were used to measure outcomes: 
The Vanderbilt Attention-deficit/Hyperactivity Assessment Rating Scale, which includes the 
Parent and Teacher Assessment forms (NICHQ, 2002) (See Appendix C) is the most frequently used 
instrument for screening, assessing, and measuring symptoms of ADHD in school-aged children.  The 
NICHQ Vanderbilt Assessment Rating Scales 2002 version is available to download and distribute in the 
public domain, provided that NICHQ is credited.  The first 18 questions of the Vanderbilt scales describe 
behavioral symptoms of ADHD that correspond to the DSM-5 diagnostic criteria for ADHD (APA, 
2013).  Additional questions screen for mood and conduct disorders that must be ruled out before 
diagnosing ADHD. 
The Vanderbilt Follow-up form – parent respondent (NICHQ, 2002) corresponds to the 
Vanderbilt Rating Scales – Parent Assessment used for initial diagnosis.  The follow-up form contains 
only the first 18 questions on the initial Vanderbilt Rating Scale, which correspond with the core 
behavioral symptoms of ADHD.  The follow-up form also includes an ADHD medication side effects 
rating scale, which facilitates an efficient, yet comprehensive assessment of the patient’s response to 
treatment and medication side effects.  It can be used to measure change by comparing pre- and post-
treatment behavioral symptom scores and is useful for monitoring responses over time.   
The KINDL Quality-of-Life Questionnaire (KINDL.org, 2017) is a validated questionnaire for 
parents that evaluates the impact of chronic health disorders on a child’s (aged 6-11years) quality of life 
(QOL).  This questionnaire (see Appendix E) is comprised of 24 questions and uses a 5-point Likert scale 
(never, seldom, sometimes, often, all the time) with weighted responses.  The questions assess 
perceptions of physical and emotional well-being, self-esteem, quality of familial and social relationships, 
school engagement, and competency (KINDL.org, 2017).   
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Design  
Once a need for change is identified, the improvement model suggests that the project should be 
designed to answer three questions:  what needs to change, how will we change it, and how will we know 
that the change is an improvement (Frankel et al., 2017)?  The model emphasizes the importance of 
carefully planning the design of both the implementation and evaluation prior to implementing change. 
During the pre-implementation phase, the project’s purpose, measured outcomes, measurement 
instruments, data collection methods, and analysis plan were determined for all three process changes to 
be implemented in the project: pharmacogenomic testing, standardized follow-up assessment 
documentation, and quality-of-life assessments.  With the three essential questions answered and the 
project’s components defined, the project was summarized in a table that confirms the logical alignment 
of the components (Frankel et al., 2017) to ensure that the final evaluation would answer the question:  is 
the change an improvement? 
The quality improvement bundle was implemented in three successive phases: (a) standardized 
ADHD follow-up assessments using the Vanderbilt Follow-up forms, (b) routine pharmacogenomic 
testing prior to prescribing medication for ADHD to children aged 6-12 years, and (c) administration of 
the KINDL Quality-of-Life Questionnaires.  The changes were independently evaluated at the end of the 
study period to determine their impact on the quality of care, outcomes, and/or quality of life of the 
children treated for ADHD practice.  
The IHI-based (2012) evaluation of the changes included implementing a tracking system that 
monitored compliance with the standardized documentation over time.  A chart review was conducted to 
evaluate the effects of implementing routine pharmacogenomic testing prior to prescribing medication for 
ADHD, using patient experiences of treatment with respect to the number of moderate and severe ADHD 
medication side effects and the amount of behavioral change as the key areas of change.  The quality of  
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life of children who are treated for ADHD at the clinical site was assessed by examining results of a  
survey sent to the parents of the participants in the pharmacogenomics evaluation.  
Table 1 summarizes the alignment of the outcomes measured, purpose of the project, methods of 
measuring outcomes, data collection, and analysis of the QI evaluation. 
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Table 1   
QI Evaluation: Alignment of Project Purpose, Outcome Measures, Methods, & Analysis 
1st Outcome 
Measure 
 
Definition 
Alignment with 
Purpose 
Alignment with 
Methods 
How Data Was 
Collected 
 
Analysis Plan 
 
Number of ADHD 
medication side 
effects rated 
moderate and/or 
severe on the 
Vanderbilt Follow-
up Form Medication 
Side Effects Rating 
Scale  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantifies the 
incidence of ADHD 
medication side 
effects that are rated 
moderate or severe   
 
 
 
The number of 
moderate and severe 
ADHD medication 
side effects indicates 
whether the patient’s 
current ADHD 
medication is 
tolerable and if the 
side effects impair 
patient’s functioning 
and or decrease 
quality of life. 
Goal: to determine 
whether 
pharmacogenomic 
testing prior to 
prescribing ADHD 
medication is 
associated with 
fewer moderate and 
severe ADHD 
medication side 
effects.  
 
Pharmacogenomic 
testing (PGT) was 
offered to all parents 
of children aged 6-
12 years who were 
prescribed 
medication to treat 
ADHD. 
 
 
 
 
 
 
 
Parents reported the 
incidence of ADHD 
medication side 
effects on Vanderbilt 
ADHD Follow-up 
forms at each visit.  
Forms were 
reviewed and scored 
by nurses; scores 
were recorded in the 
patient’s chart and in 
the EMR. A 
retrospective chart 
review of data from 
samples of children 
was extracted and 
evaluated in 
aggregate form.  
 
Comparison of the 
mean number of 
moderate and 
severe ADHD 
medication side 
effects reported by 
parents of patients 
who had 
pharmacogenomic 
testing prior to 
being prescribed 
medication for 
ADHD to the 
mean number of 
such side effects 
reported by 
parents of patients 
who did not have 
pharmacogenomic 
testing. 
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2nd Outcome 
Measure 
 
Definition 
Alignment with 
Purpose 
Alignment with 
Methods 
How Data Was 
Collected 
 
Analysis Plan 
 
Change in the 
child’s behavioral 
symptoms scores, 
determined by 
subtracting the 
behavioral 
symptoms score on 
the Vanderbilt 
Follow-Up forms 
from the behavioral 
symptom score on 
the initial Vanderbilt 
Rating Scale – 
Parent Assessment. 
 
Change in symptoms 
assessment score 
indicated whether 
the medication was 
effectively reducing 
the impairment of 
ADHD symptoms.  
Efficacious response 
was a 50% reduction 
in symptoms and 
“no impairment” 
while taking 
medication for 
ADHD. 
 
Improving treatment 
outcomes of children 
with ADHD meant 
ensuring that the 
medication was both 
efficacious and well 
tolerated.   
 
Assessing quality of 
life ensures that the 
patient experience of 
treatment and was 
also considered and 
that quality of life 
was also a goal.  
 
Vanderbilt 
behavioral symptom 
assessments allowed 
monitoring of the 
patients’ symptom 
responses to ADHD 
treatment to 
determine whether 
the treatment was 
effective as well as 
the areas in which it 
was not. 
 
Parents reported 
behavioral 
symptoms using the 
Vanderbilt Follow-
up forms at each 
ADHD follow up 
visit. Forms were 
reviewed and scored 
by nurses at check-
in; scores were 
recorded in the 
patient’s chart in the 
EMR. Retrospective 
chart review data 
from samples of 
children were 
evaluated. 
 
Change in symptom 
scores were 
recorded for each 
patient and the 
scores of patients 
who had 
pharmacogenomic 
testing were 
compared to the 
scores of current 
patients who did 
not receive testing. 
The mean score 
was calculated for 
each group and 
compared to 
determine whether 
pharmacogenomic 
testing was 
associated with 
greater change in 
behavioral 
symptoms of 
ADHD.  
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3rd Outcome 
Measure 
 
Definition 
Alignment with 
Purpose 
Alignment with 
Methods 
How Data Was 
Collected 
 
Analysis Plan 
 
Scores on the parent-
reported KINDL 
Quality-of-Life 
Questionnaire 
 
 
 
Parental perceptions 
of their child’s 
quality of life, 
determined by 24 
questions describing 
the child’s 
behaviors, which 
indicate the quality 
of parental 
relationships, 
physical and 
emotional wellbeing, 
relationships with 
friends, engagement 
in school, sense of 
competence, and 
self-efficacy.  
 
Improving the 
quality of life for 
children with ADHD 
must consider not 
only the effect of 
medications on 
symptoms of ADHD 
but also on the 
individual’s quality 
of life with respect 
to psychosocial and 
emotional  
experiences. 
Improved quality of 
life was measured by 
parental reports of 
their child’s quality 
of life. 
 
Improving the 
quality of life for 
children with ADHD 
involved improving 
the care processes to 
deliver care that was 
responsive to the 
patients’ and 
parents’ needs. 
 
 
 
 
Study:  The KINDL 
Quality-of-Life 
Questionnaire was 
mailed to parents of 
patients in the study 
groups, with a 
stamped envelope 
for anonymous 
return to the 
practice.   
 
Implementation: all 
parents of children 
aged 6-12 years, 
treated for ADHD 
were asked to 
complete a 
KINDL Quality-of-
Life Questionnaire at 
least annually.  
 
 
 
 
 
Scoring 
according to 
KINDL manual.  
Review of data, 
with comparison 
to benchmark 
values to 
determine if a 
child experienced 
poor quality of 
life and required 
further 
evaluation. 
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Data Analysis 
Data was analyzed to evaluate each outcome.  Retrospective chart review data was analyzed 
using a non-randomized control group design and basic descriptive statistics (mean, range, outliers) to 
compare outcomes of the two groups (Siriwanda, 2009; Frankel et al., 2017).  Data was analyzed by 
calculating each quality-of-life score, per the formula in KINDL manual (see Figure 1), and comparing 
outcomes to the established benchmark data and by reviewing common themes (see Table 5).  
Ethical Considerations 
No identifiers from patient charts were recorded during the data collection.  Only the doctoral 
student evaluator and practice managers know the identities of the patients who were included in the 
sample. Since the clinical site is a private practice, patient charts are stored on an electronic medical 
record (EMR) within a closed network system.  The student and practice managers only accessed the 
EMR while physically present at the implementation site.  Patients were assigned codes that were used to 
assign them to groups (see Table 3).  The doctoral student’s computer was assessed by the graduate 
school technical security supervisor; all data on the computer is encrypted and password protected.   The 
study was approved by the Office of Human Research Ethics Institutional Review Board (IRB) of the 
University of North Carolina at Chapel Hill (17-2556). 
Implementation and Evaluation Procedures 
The three process changes of the quality improvement project were implemented in accordance 
with the IHI model for improvement (Frankel et al., 2017; Demming, 2011), although, unlike PDSA 
cycles, the changes were implemented universally. Standardized ADHD follow-up documentation was 
implemented practice-wide.  All children with ADHD, aged 6-12 years, were expected to present with 
their parent for follow-up of ADHD treatment with a completed Vanderbilt Follow-up form.  All such 
children who were either failing their current therapy or initiating therapy for ADHD were offered the 
opportunity to have pharmacogenomic testing prior to being prescribed medication for ADHD.   
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Phase 1:  Implementation of the Vanderbilt Follow-up Form   
Frankel et al. (2017) are adamant about the necessity of implementing standardized 
documentation of assessments, stating that to rely on the memory and altruism of providers 
results in mediocre care.  
Implementation Procedure.  The Vanderbilt Follow-up Parent Assessment forms were 
implemented as standard documentation for every follow-up visit.  When patients presented for ADHD 
follow-up appointments, parents brought the completed Vanderbilt follow up form (NICHQ, 2002), 
which includes the same 18 questions, and rate their child’s symptoms while on the medication, and 
report any ADHD medication side effects that their child has experienced since the last visit.  During the 
intake evaluation, nurses review both the symptoms and medication side effects reported on the 
Vanderbilt Follow-up forms and record values in the electronic medical record (EMR).  ADHD 
symptoms and medication side effects are quantified and documented.  The patient’s symptoms are 
quantified as the difference between the total symptom score on the initial Vanderbilt Rating Scale Parent 
Assessment form, and the total symptoms score on the Vanderbilt Follow-up Parent Assessment form.  
The following procedures were initiated to support the implementation process.   
A. Vanderbilt Follow-up forms were mailed to the parents of all patients, aged 6-12 years, who 
were scheduled for follow-up appointments within the next two months, with an appointment 
reminder and a request to complete the form and bring it to their appointment.   
B. To ensure consistent use, the office administrators maintained a supply of Vanderbilt 
Assessment Scales and Follow-up forms. The Vanderbilt Follow-up forms were saved on the 
shared drive, accessible to all staff when needed. 
C. Upon check-out, the front desk staff provided parents with a Vanderbilt follow-up form. The 
receptionists asked parents to bring it to their next appointment.  
D. When patients returned for follow-up, the front desk staff asked the parent if they had 
completed the Vanderbilt Follow-Up form.  If they had not, the receptionist gave the parents a 
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Vanderbilt Follow-up form on a clipboard and asked them to fill it out and return it before they 
were taken back for assessment.   
E. To ensure compliance with documentation, the practice manager performed a random chart 
audit of five charts, then tracked the documentation of all patient visits for follow-up treatment of 
ADHD of patients between the ages of 6 and 12 years.   
Phase 2:  Implementation of Routine Pharmacogenomic Testing 
Pharmacogenomic testing was offered to all children with ADHD, aged 6-12 years, before being 
prescribed medication for ADHD. The implementation of pharmacogenomic testing in clinical practice was 
as described in the paragraph below.  (See Appendix B for the QI implementation protocol.) 
Implementation Procedure.  Providers educated parents and patients about the 
pharmacogenomic test, its benefits and limitations, potential co-pays, and explained that medication 
would be prescribed after reviewing the results of the test.  Nurses or providers obtained consent, then 
obtained a DNA sample using a buccal swab and packaged the sample.  Front desk administrators copy 
the patient’s insurance cards and sent the sample to the lab.  Providers ordered the test and completed the 
pre-authorization form online.  Three days later, test results were posted to the company portal, and the 
provider was notified that the results were available.  Providers reviewed the results and selected a 
medication and starting dose that was most appropriate based on the information available, including 
family history, patient physical characteristics, severity and symptoms of ADHD, the patient’s insurance, 
and the pharmacogenomic test results. Nurses contacted parents to inform them that the results had 
arrived and the provider had selected a medication and offered to leave the prescription at the front desk.   
Modifications to Side Effect and Behavioral Symptom Scoring.  During meetings, several 
providers determined that modifications to scoring the documentation were necessary.  Mild side effects 
such as an occasional mild headache would not affect treatment planning and might not even have been 
side effects of the medication.  The difference between moderate and severe were difficult to define.  
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Hence, only moderate and severe medication side effects were counted, and they were counted as single 
instances, without weighted scores. 
Additionally, patients who screened positive for some of the mood or conduct disorder symptoms 
on the initial Vanderbilt Rating Scale may have appeared (inaccurately) to have greater symptom 
improvement than children who did not exhibit conduct or mood disorder symptoms, because the initial 
Vanderbilt Assessment score counted those behaviors in the total while the Vanderbilt Follow-up only 
considered items 1-18, the behavioral symptoms of ADHD.  The difference in behavioral scores was 
therefore based only upon the difference in the score of items 1-18 on the initial Vanderbilt Rating Scale 
(parent) and the Vanderbilt Follow-up (parent) forms. 
Evaluation Procedure.  The number of ADHD medication side effects rated “moderate” and 
“severe” on each Vanderbilt follow-up form in the charts of patients in each sample group was recorded 
without identifiers in Excel.  The change in behavioral symptom scores was also calculated for each 
patient, and recorded in the EMR.  The difference in behavioral symptoms was calculated as the 
difference between the first 18 questions on the initial Vanderbilt Rating Scale – Parent Assessment and 
the Vanderbilt Follow-up forms.  The means and range of each group were compared.  Demographic data 
was collected to ensure similarity in age and gender mix of the study sample populations. 
Implementation of the Quality-of-Life Questionnaire  
Information in the initial KINDL Quality-of-Life Questionnaire survey, in which the identities of 
the respondents and children were unknown, indicated a need for further evaluation and referrals.  This 
prompted the practice to implement the KINDL Quality-of-Life Questionnaire as an annual assessment 
for all children between the ages of 6-12 years with ADHD.  
Implementation Procedure.  Nurses provided the questionnaire to parents on a clipboard, to 
complete in the room during the review of the current complaint and health information. Once the KINDL 
Questionnaire had been reviewed and scored, providers placed a practice alert in the patient’s hub and the 
note appeared in a yellow box, “2018 KINDL completed on [date].”  If the score was within the standard 
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deviation of the normal range and no responses raised red flags, the questionnaire was filed in the chart.  
If the score was low or responses raised questions, the primary care providers assessed further and 
referred the child to a pediatric psychiatrist for further evaluation.   
Implementation of the Quality-of-Life Survey 
The quality-of-life survey assessed the quality of life of children with ADHD and the potential 
effect of pharmacogenomic testing on quality of life.  The practice initially surveyed the quality of life of 
children with ADHD using the KINDL Quality-of-Life Questionnaire (KINDL.org, 2017; see Appendix 
D) by mailing it to 40 parents of children with ADHD, allowing parents to respond anonymously when 
returning the forms.  Some parents called to learn their child’s score and the interpretation of the score.  
This generated discussion about quality of life that proved valuable.  
Survey Evaluation Procedure.  The survey was returned by 18 of 40 parents.  Upon receipt of 
the surveys, the quality-of-life score for each child was calculated according to the formula provided in 
the KINDL Quality-of-Life Questionnaire Manual (see Figure 1).  Mean scores were calculated for each 
study group and for the study population.  The mean scores of patients who had pharmacogenomic testing 
were compared to the scores of patients who did not have pharmacogenomic testing.  Scores of the total 
population were compared to the baseline reference values of other school-aged children with ADHD, 
established by the OBSEER trial (see Table 3), and to the values of neurotypical school-aged children 
without chronic health disorders, established in the BELLA trial (see Table 3).  Figure 1 presents the 
formula for calculating quality-of-life scores using the KINDL. 
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Evaluation of the Quality of Care  
The value of quality of care is subjective and measured in the context of individual experiences 
and expectations.  The success of this project’s efforts to improve quality of care was based on 
information provided by parents of patients in interviews following their child’s follow-up visits for 
treatment of ADHD.  Parents were informed of the quality improvement implementation and the study 
and asked to provide feedback about what was helpful as well as make suggestions for improvement.  
During staff meetings, providers and clinical staff at the implementation site also evaluated the impact of 
the interventions, which were considered in the final evaluation. 
 
 
 
Figure 1. Formula for Calculating KINDL Quality-of-Life Scores 
 
Sum score = sum of sub-scale items (4 questions) 
 
Sub-scale score = sum of sub-scale items / number of sub-scale items (24) 
 
Total sub-scale score = sum of 24 items/24 
 
Transform to 100 = sub-scale score – lowest possible score 
Possible range of raw score 
Quotient X 100 
Figure 1. Formula used to calculate individual scores of parent KINDL Quality-of-
Life Questionnaires. (Ravens-Sieber, Erhart, Willie, & Bullinger, 2008, pp. 18-22). 
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CHAPTER 5: RESULTS 
 
The three practice improvements were fully implemented:  1) implementation of standardized 
comprehensive assessments of symptom response and ADHD medication side effects using the 
Vanderbilt Follow-up form, 2) routine pharmacogenomic testing for ADHD medication prescribed to 
children, and 3) annual quality-of-life assessments of children with ADHD using the KINDL Quality-of-
Life Questionnaire.  This report describes the outcomes as of December 1, 2017, although implementation 
at the clinical site is ongoing. The results of the quality improvement implementation evaluations are 
reported in accordance with the Squire 2.0 (2018) reporting guidelines for quality improvement projects.   
Evaluation of Documentation Compliance  
Between October 5, 2017, and December 1, 2017, documentation compliance improved.  
Initially, only 49% of the charts of current school-aged patients with ADHD contained both the 
Vanderbilt Rating Scales Parent and Teacher Assessments and the Vanderbilt Follow-up forms.  
However, based on the last audit, the clinic is incorporating the QI documentation model into their 
charting and clinical practices.  On December 1, 2017, 77% of visits for ADHD in the past month 
contained documentation of the appropriate behavioral symptoms and/or medication side effects on 
Vanderbilt forms, which were scanned into the patient documents. Problems that persisted included: (a) 
no name on the form, which prevents administrators from filing the form into a patient’s chart; (b) no 
date, which prevents the data from being useful since it cannot be related to a specific course of treatment; 
(c) inconsistent use of the ADHD follow-up visit template in the EMR; and (d) proper scoring of the 
Vanderbilt Follow-up forms.  In-services were planned to review scoring and interpretation of the 
Vanderbilt Assessment Scales, the diagnostic criteria for ADHD, and the necessity for entering scores in 
the EMR using the template.  
Providers’ responses to the standardized documentation were unanimously positive.  Providers 
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agreed that quality of care is enhanced by using the Vanderbilt Follow-up forms because the standardized 
assessments are more comprehensive than the previous practice of asking open-ended questions about 
symptoms, side effects, and performance.  Providers also agreed that their treatment plans are more 
thorough and more patient-specific because the forms provide comprehensive assessment information 
within two minutes, which allows time for the providers to focus discussions on specific concerns. Since 
maintaining JACHO accreditation as a primary care medical home is contingent upon demonstration of 
continuous quality improvement, the responsibility for ensuring compliance with the documentation is 
managed by the practice’s internal QI committee.  
Results of the Pharmacogenomic Testing Evaluation 
The evaluation of pharmacogenomic testing was conducted by using retrospective chart review 
data to evaluate whether pharmacogenomic testing prior to prescribing medication for ADHD was 
associated with a significant difference in the reported number of medication side effects and the amount 
of behavioral change.  The chart review included charts of 52 patients aged 6-12 years who were treated 
at the practice for ADHD in 2016.  The two study groups comprised 46% of the population of children 
aged 6-12 years who were treated for ADHD at the implementation site in 2016 (n = 112).  The patient 
charts were divided into two groups according to their history (PGT) or absence of history (No PGT) of 
pharmacogenomic testing for psychotropic medications; the first 26 patients in each group who met study 
inclusion criteria were selected as study participants.  
Demographic data.  Each sample was comprised of 26 patients.  The PGT group was comprised 
of 20 boys and 6 girls; patients ranged in age from 6-13 years old, with a mean age of 9 years.  The No 
PGT group was comprised of 18 boys and 8 girls, with a mean age of 9 years, 6 months.  Racial 
composition was:  4 bi-racial children (2 African American-Caucasian, 2 Hispanic-Caucasian), 4 
Hispanic, 20 African American, and 24 Caucasian children.  The total number of visits per patient ranged 
from 1-7, with an average of 2.5 visits per patient.       
  
 37 
Medication Side Effects.  Pharmacogenomic testing prior to prescribing medication for ADHD 
was associated with lower mean incidences of parent-reported moderate and severe ADHD medication 
side effects.  The average number of side effects experienced by patients in each group was compared 
(see Table 2).  The PGT group reported an average of 1.1 moderate or severe side effects, with a range of 
0-4, whereas the mean number of moderate or severe side effects reported by the No PGT group was 2.4 
with a range of 0-6. 
Behavior Change.  The study participants who received pharmacogenomic testing also had a 
greater improvement in behavioral symptoms after taking medication for ADHD. The difference in 
behavioral symptoms indicated by the Vanderbilt initial assessment and the follow-up assessment 
behavioral symptom scores was (PGT -32 vs. No PGT -15.8) (see Table 2).  
Table 2 presents the data collected in the retrospective chart review, indicating the difference in 
behavioral scores and the number of moderate and severe ADHD medication side effects reported by 
participants in each group.   
Table 2  
Evaluation of the Effects of Pharmacogenomic Testing on Changes in Behavioral  
Symptoms and Incidence of Moderate or Severe ADHD Medication Side Effects for 
Children Receiving and Not Receiving Pharmacogenomic (PGT) Testing 
Group Change in 
Symptoms 
# of SE Group Change in 
Symptoms 
# of SE 
      
PGT-1 -17 0 NO PGT-1 -11 2 
PGT-2 -25 0 NO PGT-2 -38 2 
PGT-3 -34 0 NO PGT-3 -26 4 
PGT-4 -48 0 NO PGT-4 -22 0 
PGT-5 -69 0 NO PGT-5 0 0 
PGT-6 -60 3 NO-PGT-6 6 0 
PGT-7 -37 2 NO PGT-7 -20 1 
PGT-8 -17 0 NO PGT-8 -5 6 
PGT-9 -30 1 NO PGT-9 -2 1 
PGT-10 -24 0 NO PGT-10 -20 1 
PGT-11 -37 5 NO PGT-11 -20 1 
PGT-12 -36 3 NO PGT-12 -8 8 
PGT-13 -43 2 NO PGT-13 -6 6 
PGT-14 -45 2 NO PGT-14 -4 5 
PGT-15  -36 2 NO PGT-15 -25 6 
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Group Change in 
Symptoms 
# of SE Group Change in 
Symptoms 
# of SE 
PGT-16 -17 0 NO PGT-16 -6 0 
PGT-17 -15 2 NO PGT-17 -17 2 
PGT-18 -18 3 NO PGT-18 -7 2 
PGT-19 -15 0 NO PGT-19 -27 5 
PGT-20 -24 1 NO PGT-20 -38 1 
PGT-21 -19 0 NO PGT-21 -12 3 
PGT-22 -51 0 NO PGT-22 -30 0 
PGT-23 -45 1 NO PGT-23 -20 0 
PGT-24 -31 1 NO PGT-24 -7 4 
PGT-25 -17 1 NO PGT-25 0 3 
PGT-26 -22 0 NO PGT-26 -64 3 
MEAN -32 1.1 MEAN -15.8 2.4 
      
Note. Changes in Vanderbilt Behavioral Scores = Initial Rating Scale (Parent) score -  
Follow-up (Parent) score; Number of ADHD Medication Side Effects = Number of side 
effects are reported as “moderate” or “severe” 
 
Results of Quality-of-Life Assessments 
Demographics.  The sample was comprised of 18 patients, including 11 boys and 7 girls.  
Patients ranged in age from 6 to 13 years old, with a mean age of 9 years old. 
Survey Results.  The parent KINDL questionnaire was completed by 18 of 40 parents. The mean 
quality-of-life score of the study population was 75.6. The results of the survey as well as the population 
and subgroup totals are reported in Table 3.  Although the values of the PGT group were higher, the small 
sample size (n = 3) prohibits generalization of the results (IHI, 2012).  The unidentified respondents are 
more likely to have been patients who had not received pharmacogenomic testing, and if those three 
scores were added to the established No PGT average, the group score would be lowered to 74.7. Table 3 
depicts the quality-of-life scores of the study participants. 
Table 3  
 
Results of the KINDL Quality-of-Life Questionnaire Survey of Study Participants 
 
PGT Group (N = 3)   Avg. 80.3 
Pt. Scores:  93, 74, 74 
 
No PGT Group (N = 12)  Avg.  75.5 
Pt. Scores:  79, 84, 91.6, 58, 61.5, 73.9, 70.8, 73, 78.1, 94.7, 72, 69.8, 71.6 
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Unknown Affiliation (N = 3)    Avg. 71.2 
80.2, 72, 61.5 
 
Study Population (N = 18) Avg. 75.6 
 
Range:  58 – 94.7 
 
Average NPGT Group score after eliminating highest and lowest scores:  75.5 
 
Trends in Responses.  The KINDL questionnaire respondents consistently affirmed positive 
parenting and family relationships and physical well-being for their children, especially in response to 
questions in which parents rated their child as “always” or “often” full of energy, “never” feeling alone, 
and “never” feeling afraid. The scores dipped in response to the self-esteem item, “my child has lots of 
good ideas,” which was most frequently responded to with “sometimes” or “often,” although one parent 
responded “rarely.”  
Responses varied in parents’ assessments of their children’s self-esteem and scholastic 
engagement.  Parents also reported a variety of responses to the question asking whether their child “felt 
different from other children” and was “interested in the lessons taught at school.”  These three low scores 
(58, 61.5, 61.5) are on par with the average KINDL parent-rated quality-of-life score of children with 
ADHD as reported in the OBSEER study (Becker, 2011, pp. 61-65).  To put these numbers in 
perspective, the KINDL.org site (2017) posts 0.85 as the normal value for children aged 6-11 years 
without chronic health disorders, as established by the multi-centered KIGGS trial in Germany.  
However, the KIGGS study is not translated to English.  The literature in English consistently refers to 
the “normal” reference values established by the BELLA trial, which is 76.3 in neurotypical children, 
aged 6-11 years, without chronic health disorders (Becker et al., 2011, p. S271). 
Study Participants Compared to Benchmark Averages.  The quality-of-life scores of the 
population of school-aged children with ADHD treated at the implementation site are on par with 
reference values of parent-reported KINDL Quality-of-Life Questionnaire scores of neurotypical children 
without chronic health disorder diagnoses (76.3).  The scores of children with ADHD at the study site 
exceed the established benchmark average quality-of-life scores for children aged 6-11 years with ADHD 
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(62.9) as reported on the parent KINDL (Becker, et al., 2011).  Benchmark reference values are reported 
in Table 4. 
Table 4  
 
Comparison of Benchmark Quality-of-Life Scores Using the KINDL 
Questionnaire: Children without Chronic Health Disorders (BELLA) vs. 
Children with ADHD (OBSEER) (Adapted from: Becker et al., 2011, p. 
S271) 
 
 BELLA  
(n = 2,863) 
OBSEER  
(n = 721) 
d T 
Total Score 76.3 (SD 10.1) 62.9 (SD 13.3) 1.1 30.51 
Physical well-being 76.5 (17.3) 71.4 (18.3) 0.3 6.52 
Emotional well-being 80.8 (12.8) 67.6 (17.6) 0.9 22.51 
Self-esteem 68.8 (14.2) 55.1 (18.5) 0.8 21.84 
Family 77.7 (14.3) 62.2 (19.4) 0.9 24.95 
Friends 78.0 (13.4) 60.2 (20.9) 1.0 24.31 
School 76.0 (16.0) 60.9 (18.7) 0.9 20.10 
 
Evaluation of the Quality of Care 
  Client Feedback.  Parents’ perceptions of the quality and experiences of care were obtained 
through a series of informal interviews at the clinical site.  Responses to the implementation of 
pharmacogenomic testing have been consistently very positive.  A typical response was that of a mother 
who reported that she had cried throughout her first three visits because she was upset at the thought of 
medicating her son, but was also fearful of the consequences of not effectively treating his symptoms. 
After treatment as described in this study, she remarked that she was very pleased by the quality of care 
her son received and felt reassured that the ADHD treatment prescribed was safe, appropriately 
monitored, and in his long-term best interests, which took a weight off her shoulders.  She stated that 
“The pharmacogenomic testing was part of the whole care package,” which indicated to her that the care 
was individualized, careful, and caring.  One strong vote of confidence came when she recommended our 
practice to a friend whose son had been diagnosed with ADHD and whose father had refused to allow him 
to take medication.  After the friend’s son was brought in by his father, a provider confirmed the son’s 
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diagnosis of ADHD and administered the pharmacogenomic test.  The father was adamantly against his 
son taking medication to treat ADHD.  He appreciated our approach however, and came back and agreed 
to try medication after it was pointed out that the medication might help his son to have better impulse 
control in situations outside of school. His son’s pharmacogenomic report indicated that he was an 
abnormal metabolizer of all FDA-approved medications for treatment of ADHD in children.  This spared 
the child and family at least one, if not two, unnecessary trials of different classes of stimulants. The 
child’s father remarked that he “felt more comfortable moving forward.…  Now I understand why I had 
such a hard time.  It’s not that all the medicines do that.”  He later agreed that, “He [his son] is on the 
right medicine.” 
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CHAPTER 6: DISCUSSION 
 
The quality improvement project achieved its purpose. Parents of children with ADHD, 
providers, and administrative and clinical staff at the implementation site all positively appraised the 
changes implemented so far and stated that the changes improved both the quality and the outcomes of 
care. Despite the missing documentation and subsequently skewed distribution of the study groups, which 
precluded statistical significance for the chart review results, implementing routine pharmacogenomic 
testing was judged valuable by providers at the clinical site because the study population was comprised 
of 46% of the target population and the groups were demographically similar, eliminating other 
confounders.  The small sample size of the quality-of-life survey (18 of 40) prohibits generalization of its 
results, yet the consistency of the relatively high quality of life reported by parents of children with 
ADHD is encouraging. Although the KINDL Quality-of-Life Questionnaire scores are primarily 
attributable to the children’s family and social networks, the consistency of the positive scores among 
survey respondents indicates that the system is working effectively to support the healthy development of 
resilience among an exceptionally large percentage of children with ADHD. 
Attributes 
 
This quality improvement project was unique in many respects.  Implementation of the quality-
of-life evaluations inserted this dimension, with its implications for psychosocial resilience, into the 
equation for measuring outcomes in children with ADHD.  QoL has not previously been stipulated as a 
standard treatment outcome for children with ADHD.  However, providers at the implementation site 
unanimously agreed that the development of resilience via improved QoL should be considered a 
treatment goal for school-aged children with ADHD.  That formal consensus supported the 
implementation of the quality-of-life survey assessment for all children with ADHD and compelled a 
discussion with parents about the long-term goals of treatment.  
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The obvious and most compelling benefit of assessing quality of life is to improve outcomes by 
identifying patients with poor quality of life to facilitate the early interventions necessary to forestall 
development of comorbid behavioral health disorders (Danckaerts et al., 2010).  Discussion among 
healthcare providers and with parents about quality-of-life assessments improves the quality of care.  
Talking about a child’s quality of life in a warm and supportive manner invites parents to partner with 
their child’s healthcare providers in promoting the factors leading to resilience.  In addition, the 
discussion opens potentially therapeutic channels of communication between parents and children about 
situations that the child finds problematic, providing an opportunity for children to be heard and 
validated.  The discussion allows healthcare providers to partner with the parents, demonstrate “positive 
parenting,” and encourage children to articulate their concerns and solve problems.  Assessments 
indicating a good quality of life are valuable because they briefly shift the focus of the discussion away 
from the reports of a child’s behavior and performance last week, to considering the goals of treating 
ADHD, such as healthy development and quality of life, both of which support resilience and promote 
lifelong good health.   
Small-Scale Quality Improvement Evaluations.  Quality improvement with continuous 
monitoring has become an important means of translating evidence into practice and of improving the 
outcomes and quality of healthcare (IHI, 2012).  Routinely offering pharmacogenomic testing before 
prescribing medication to treat ADHD in children is an example of a quality improvement 
implementation that may further our knowledge and change our practices.  The refinement of our methods 
will further validate quality improvement findings as legitimate evidence, which will empower 
individuals and small practices with the means of transforming at least one piece of the system of 
healthcare.   
Rogers’ (2003) discussion of the diffusion of innovations describes, explains, and predicts how, 
why, and at what rate new ideas and practices are adopted within a society. The theory has been widely 
applied to the adoption of healthcare innovations because it is a translational theory that predicts the 
perception of the external validity of innovations (Cain & Mittman, 2002).  His theory can be used to 
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explain the slow adoption of pharmacogenomic testing among the medical community, which is due to 
the lack of large, randomized, controlled clinical trials. The theory of the diffusion of innovations asserts 
that smaller organizations with leaders who are visionary and respected opinion leaders will serve as the 
innovators and early adopters of innovations in a society, while larger organizations will be more risk-
averse, late-majority adopters (Cain & Mittman, 2002).  Small practices are positioned to take the lead in 
the adoption of innovations in healthcare because they are more flexible and able to adapt systems to 
incorporate innovations.  A sense of community allows for the more cooperative work flow necessary to 
implement new processes into clinical routines.  
Limitations 
This study was limited by the small sample sizes and prior history of poor documentation, 
particularly when patients were satisfied with their outcomes, which skewed the distribution of the No-
PGT pharmacogenomic testing sample. Those unavoidable factors prevented the inclusion of a larger 
number of patients who would meet the study criteria and the more balanced distribution of samples that 
would have followed.  Problems with documentation were revealed by the QI evaluation, addressed, and 
resolved, thus improving both the quality of care and the efficiency of delivery.  The study only viewed 
quality of life from the parental perspective due to the time limitations of the study period and the 
potential time required by the IRB to authorize the inclusion of child respondents.   
Recommendations for Future Studies 
The IHI (2012) advocates the creation of a learning-oriented healthcare system in which 
healthcare providers share mistakes as well as successes to advance the evolutionary plane of knowledge.  
Quality improvement clinical implementation projects are fraught with unanticipated challenges and 
missteps that must be addressed before the desired change can be implemented and proven to be an 
improvement. QIs are typically real-world implementations led by individuals without research 
backgrounds in settings over which they have limited control. Yet learning from others about what not to 
do in a situation or how to anticipate a problem would be helpful to others in the field. In a transparent 
system, these non-academic QI leaders would be able to share their procedures, findings, and mistakes in 
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the literature, which could then be read by individuals with similar interests, who might thereby be 
forewarned not repeat the same mistakes in a similar project. To be truly helpful, future studies should 
focus not only on the results of the evaluations but also detail the processes involved as often-
inexperienced clinicians and teams work to implement changes at the practice level, leaving a trail so that 
others following in their footsteps would be able to go farther.   
Future studies should attempt to accurately characterize the value of successfully treating ADHD 
in children by selecting a much larger sample of children with confirmed diagnosis of ADHD who take 
medication for the condition, children who report improvement of ADHD symptoms and no moderate or 
severe medication side effects.  Their outcomes should then be compared to those of neurotypical children 
who do not have ADHD.  Numerous studies report that treatment for ADHD is associated with lower risk 
of developing substance abuse and/or eating disorders, dying in a motor vehicle accident compared to 
peers with ADHD who do not take medication (Biederman, 2003; Charach et al., 2011, Dalsgaard et al., 
2015; Ruiz et al., 2017).  However, existing the studies do not indicate the remission status of the children 
taking ADHD medication.  Hence, there is a possibility—even a probability—that the results may be 
skewed, with children with ADHD who are successfully treated enjoying a high level of risk reduction, 
while children who have responded poorly to their current medication or who only experience a moderate 
reduction or no reduction of risks, reported in aggregate, pull the risk reduction level down. 
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CHAPTER 7: CONCLUSION 
Overall, the evaluation results of this quality improvement implementation indicate that the 
project has successfully furthered its goals of improving the quality of life and quality of care for school-
aged children with ADHD at the implementation site.  The high quality-of-life scores reported by the 
survey respondents, fewer incidences of moderate and severe ADHD medication side effects, and greater 
change in behavioral symptom scores in the group of patients who received pharmacogenomic testing all 
support an appraisal of the changes as improvements.  Despite an inability to generalize the findings 
based on the limited data available at the time of the evaluation, providers agreed that the findings 
justified continuing implementation of the innovations in their clinical practice.  The 52 study participants 
accounted for 46% of the total population of children between the ages of 6 and 12 years who were 
treated at the practice in 2016.  Ignoring the findings and reverting to the previous routine, they felt, 
would defy common sense.  
Although the evaluation results found that the changes were improvements, the hypothesis 
underlying the study design was never proven as true or untrue.  This is significant because it leaves 
uncertainty about the approach that healthcare providers should take to address the issues of quality of life 
and resilience.  Further, it leaves uncertainty about the value of individual interventions even within the 
same population.  The underlying hypothesis of the project was that the relative lack of resilience among 
children with ADHD, reflected in consistent reports of poor quality of life, is largely attributable to the 
unremitting symptoms of ADHD and ADHD medication side effects.  ADHD side effects often decrease 
a child’s social and academic engagement and thus subsequently decrease resilience.  However, the 
literature consistently finds that improving the long-term health of children with ADHD begins by 
furthering resilience (Perese, 2012; Masten, 2014).  Since resilience is inextricably connected to quality of 
life, improving quality of life would be a means of promoting resiliency in children. This project was 
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designed to improve quality of life, starting by decreasing the number and severity of ADHD medication 
side effects, improving treatment efficacy, and formally assessing quality of life as a treatment outcome.   
Since the implementation of quality-of-life assessments and standardized follow-up assessments 
is readily available, this hypothesis may be tested in future studies.  Charting points on a scatter plot may 
reveal a linear relationship between the number of moderate and severe ADHD medication side effects on 
the vertical axis and quality-of-life scores on the horizontal axis (IHI, 2012).  Another avenue worth 
further exploration is the issue of whether pharmacogenomic testing improves the quality of care, in part, 
by providing reassurance to parents and providers that the treatment plan is optimized, even when the 
results themselves do not significantly alter the provider’s choice of treatment. 
Some of the implications for clinical practice were discovered during the QI process rather than 
being anticipated at the design stage.  Quality-of-life assessments, for example, potentially improve 
outcomes by identifying patients with poor quality of life and fewer factors contributing to resilience.  
This improvement is possible because assessing a child’s quality of life in a warm and supportive manner 
invites parents to partner with health care providers, which promotes the positive reinforcement of 
resilience and raises awareness of the larger goals of treating the child’s ADHD symptoms.  
Quality improvement projects are implemented with the understanding that modifications will no 
doubt occur and with plans for continuous monitoring and improvement (Frankel et al., 2017).  In this 
project, this process, by design, generated information about how to improve the delivery of care to 
maintain efficiency as well as to improve quality.  The evaluations, rather than damaging the project, 
rallied the support of the administrative staff, helping to spur the design of a systematic data collection, 
chart auditing, and a QI evaluation process that will allow the next evaluation to be truly meaningful.  
This report assesses the outcomes of the QI implementation as of December 1, 2017, but the 
implementation is ongoing; the site’s internal quality improvement team has assumed responsibility for 
continuing to collect data for ongoing evaluation of outcomes in collaboration with their JACHO 
representative. 
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APPENDIX A 
DSM-5 DIAGNOSTIC CRITERIA FOR ADHD 
 
DSM-5 Diagnostic Criteria for Attention-Deficit/Hyperactivity Disorder 
A. A persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with 
functioning or development, as characterized by (1) and/or (2) 
1.      Inattention: Six (or more) of the following symptoms, which have persisted for at least 6 
months, to a degree that is inconsistent with developmental level, and that negatively impact social 
and academic/occupational activities. Note: The symptoms are not solely a manifestation of 
oppositional behavioral, defiance, hostility, or failure to understand tasks or instructions.  For 
older adolescents and adults (age 17 and older), at least five symptoms are required. 
a.       Often fails to give close attention to details or makes careless mistakes in 
schoolwork, at work, or during other activities (e.g., overlooks or missing details, work is 
inaccurate). 
b.      Often has difficulty sustaining attention in tasks or play activities (e.g., has difficulty 
remaining focused during lectures, conversations, or lengthy reading). 
c.       Often does not seem to listen when spoken to directly (e.g., mind seems elsewhere, 
even in the absence of any obvious distraction). 
d.      Often does not follow through on instructions and fails to finish schoolwork, chores, 
or duties in the workplace (e.g., starts tasks but quickly loses focus and is easily side-
tracked). 
e.       Often has difficulty organizing tasks and activities (e.g., difficulty managing 
sequential tasks; difficulty keeping materials and belongings in order; messy, disorganized 
work; has poor time management; fails to meet deadlines). 
f.       Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental 
effort (e.g., schoolwork or homework; for older adolescents and adults, preparing reports, 
completing forms, reviewing lengthy papers). 
g.      Often loses things necessary for tasks or activities (e.g., school materials, pencils, 
books, tools, wallets, keys, paperwork, eyeglasses, mobile telephones). 
h.      Is often easily distracted by extraneous stimuli (for older adolescents and adults, 
may include unrelated thoughts). 
i.        Is often forgetful in daily activities (e.g., doing chores, running errands; for older 
adolescents and adults, returning calls, paying bills, keeping appointments). 
  
2.      Hyperactivity and impulsivity: Six (or more) of the following symptoms have persisted for 
at least 6 months to a degree that is inconsistent with developmental level and that negatively 
impacts directly on social and academic/occupational activities. Note: The symptoms are not 
solely a manifestation of oppositional behavioral, defiance, hostility, or failure to understand tasks 
or instructions.  For older adolescents and adults (age 17 and older), at least five symptoms are 
required. 
a.       Often fidgets with or taps hands or feet or squirms in seat. 
b.      Often leaves seat in situations when remaining seated is expected (e.g., leaves his or 
her place in the classroom, in the office or other workplace, or in other situations that 
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require remaining in place). 
c.       Often runs about or climbs in situations where it is inappropriate. (Note: In 
adolescents or adults, may be limited to feeling restless.) 
d.      Often unable to play or engage in leisure activities quietly. 
e.       If often “on the go,” acting as if “driven by a motor” (e.g., is unable to be or 
uncomfortable being still or extended time, as in restaurants, meetings; may be 
experienced by others as being restless or difficult to keep up with). 
f.       Often talks excessively. 
g.      Often blurts out an answer before a question has been completed (e.g., completes 
people’s sentences; cannot wait for turn in conversation). 
h.      Often has difficulty waiting his or her turn (e.g., while waiting in line). 
i.        Often interrupts or intrudes on other (e.g., butts into conversation, games, activities; 
may start using other people’s things without asking or receiving permission; for 
adolescents and adults, may intrude into or take over what others are doing). 
  
B.  Several inattentive or hyperactive-impulsive symptoms were present prior to age 12 years. 
 
C.  Several inattentive or hyperactive-impulsive symptoms are present in two or more settings 
(e.g., at home, school, or work; with friends or relatives; in other activities). 
 
D. There is clear evidence that the symptoms interfere with, or reduce the quality of, social, 
academic, or occupational functioning. 
 
E.  The symptoms do not occur exclusively during schizophrenia or another psychotic 
disorder and are not better explained by another mental disorder (e.g., mood disorder, anxiety 
disorder, dissociative disorder, personality disorder, substance intoxication or withdrawal). 
 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). 
Arlington, VA: American Psychiatric Publishing  
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APPENDIX B 
ADHD QI IMPLEMENTATION PROTOCOL 
 
Information about Our QI Implementation 
 
As many of you know, our practice has begun implementation of a quality improvement (QI) initiative to 
improve the quality of care, outcomes, and quality of life for school-aged children with attention deficit 
hyperactivity disorder (ADHD).  
 
ADHD in childhood is a significant risk factor for the development of other psychiatric disorders later in 
life.  Resilience is the strongest predictors of good mental health later in life. A stimulant medication may 
increase focus and decrease impulsivity, and be “efficacious” while a child may be suffering a flattened 
affect, and persistent anxiety, which leads to social inhibition, disengagement, and decreased self-
efficacy.  These factors of resilience in school-aged children are crucial to strengthening psychosocial 
resilience, exhibited in a child’s social skills, initiative, pride, and belief in his or her competence.  We 
hope to increase resilience by decreasing the medication side effects and by increasing our awareness of 
the child’s experience of treatment of the balance between efficacy and social engagement.   
 
     The guidelines for the management of school-aged children with ADHD in primary care were 
published in 2011, prior to the reclassification of ADHD in the DSM-5 as a neurodevelopmental disorder, 
rather than a behavioral disorder.  The treatment of ADHD in school-aged children continues to reflect 
the conception of ADHD as a behavioral disorder, with a goal of decreasing impairment by remission of 
the externalized behaviors that characterize ADHD.  As a primary care medical home, our goal is to 
provide comprehensive, patient-centered care to improve the health and wellbeing of individuals over 
their lifespans, accomplished, essentially, by identifying and reducing risk factors and increasing 
protective factors, such as resilience.   
 
To avoid medication side effects, and taking medications that may not work, we have implemented 
routine offering of the GeneSight ADHD test for all kids aged 6-12 who are newly treated in our practice. 
We have implemented the Vanderbilt Follow-up form, to assess the child’s response to pharmacotherapy 
on the behaviors identified as problematic in the initial assessment, and, to identify moderate or severe 
side effects that may necessitate a dosing adjustment or medication change.  Our goal is to reduce 
symptoms to the point where the child feels competent, without suffering medications side effects.  The 
child should feel that he or she can do what they need to with respect to their schoolwork, and exercise 
age-appropriate impulse control, yet eat dinner and fall to sleep at bedtime.   
 
When the child has been treated for at least 3 months, we will ask parents to complete the KINDL 
Quality-of-Life Questionnaire.  This questionnaire corresponds with the factors of resilience and helps us 
to identify kids who need extra support so that we can intervene early.  If the child is maintaining 
psychosocial resilience during his ADHD treatment, and ensures that our treatment plan is not only 
keeping him out of trouble in school now, it is also supporting his wellness for years to come. 
 
ADHD Quality Improvement Implementation Protocol 
 
1.  Upon diagnosis of ADHD, providers will give parents the option of having their child tested with 
the GeneSight pharmacogenomic test before prescribing medicine to treat their ADHD.  The test 
can be offered to the parents of every child aged 6-12 years who will be prescribed medication for 
ADHD. 
 
If parents bring the child in for an initial ADHD evaluation, and describe behavior that meets diagnostic 
criteria for ADHD, which has occurred in two or more settings for at least six months, and the child’s 
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clinical presentation is consistent with ADHD, providers will order the GeneSight test when they provide 
parents the parent and teacher Vanderbilt assessment forms.  This will avoid a delay in treatment once the 
diagnosis is confirmed. 
 
If the child’s diagnosis is unclear, providers will wait to test until the parent and child return with both 
Vanderbilt forms, and confirm the diagnosis, but will provide the information about the GeneSight test at 
the initial visit. 
 
*The provider may order the test, and a proxy may complete the information on the GeneSight website 
from the provider’s notes.   
 
2.  Parents will be educated about the benefits of test, and its limitations at the initial ADHD visit at 
NSMC.  We should give them the information from Assurex Health regarding their financial 
responsibility at the first visit.  
 
*Explanation of the risks and benefits, and financial responsibility follows the protocol. 
 
3.  At each ADHD follow-up visit, all parents of children aged 6-12 will complete the Vanderbilt 
Follow-Up form, which will be reviewed by providers prior to prescribing the next medication.  If they 
did not bring it with them, the ladies at the front desk will provide the form for them to complete when 
they arrive.   
 
4.  Nurses will review the ADHD Follow-Up form to ensure that it is complete, and scored correctly, ad 
will enter scores for:  
A.  the behavioral section 
B.  the total number of moderate or severe medication side effects 
 
*The performance score is contextual information only and is not scored. 
 
5.  Once the treatment plan is determined, and the patient is only returning for 3-month follow-up 
appointments, parents will be asked to complete the KINDL Quality-of-Life Questionnaire to assess 
the child’s quality of life and ensure that he is developing psychosocial resilience while he is treated for 
ADHD.   
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APPENDIX C 
NICHQ VANDERBILT ASSESSMENT SCALES 
 
 
VANDERBILT ASSESSMENT FORM – PARENT 
 
Each rating should be considered in the context of what is appropriate for the age of your 
child. 
When completing this form, please think about your child’s behaviors in the past 6 
months. 
Is this evaluation based on a time when the child: 
                                     was on medication     was not on medication      not sure? 
 
  
Symptoms 
N
ev
er
 
O
cc
as
io
n
-
al
ly
 
O
ft
en
 
V
er
y
 
O
ft
en
 
1. Does not pay attention to details or makes 
careless mistakes with, for example, homework 
0 1 2 3 
2. Has difficulty keeping attention to what needs to be done 0 1 2 3 
3. Does not seem to listen when spoken to directly 0 1 2 3 
4. Does not follow through when given directions and fails to 
finish activities (not due to refusal or failure to understand) 
0 1 2 3 
5. Has difficulty organizing tasks and activities 0 1 2 3 
6. Avoids, dislikes, or does not want to start tasks that require 
ongoing mental effort 
0 1 2 3 
7. Loses things necessary for tasks or activities (toys, 
assignments, pencils, or books) 
0 1 2 3 
8. Is easily distracted by noises or other stimuli 0 1 2 3 
9. Is forgetful in daily activities 0 1 2 3 
10. Fidgets with hands or feet or squirms in seat 0 1 2 3 
11. Leaves seat when remaining seated is expected 0 1 2 3 
12. Runs about or climbs too much when remaining seated is 
expected 
0 1 2 3 
13. Has difficulty playing or beginning quiet play activities 0 1 2 3 
14. Is “on the go” or often acts as if “driven by a motor” 0 1 2 3 
15. Talks too much 0 1 2 3 
16. Blurts out answers before questions have been completed 0 1 2 3 
17. Has difficulty waiting his or her turn 0 1 2 3 
18. Interrupts or intrudes in on others’ conversations and/or 0 1 2 3 
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Symptoms 
N
ev
er
 
O
cc
as
io
n
-
al
ly
 
O
ft
en
 
V
er
y
 
O
ft
en
 
activities 
19. Argues with adults 0 1 2 3 
20. Loses temper 0 1 2 3 
21. Actively defies or refuses to go along with adults’ requests or 
rules 
0 1 2 3 
22. Deliberately annoys people 0 1 2 3 
23. Blames others for his or her mistakes or misbehaviors 0 1 2 3 
24. Is touchy or easily annoyed by others 0 1 2 3 
25. Is angry or resentful 0 1 2 3 
26. Is spiteful and wants to get even 0 1 2 3 
27. Bullies, threatens, or intimidates others 0 1 2 3 
28. Starts physical fights 0 1 2 3 
29. Lies to get out of trouble or to avoid obligations (i.e.,  “cons” 
others) 
0 1 2 3 
30. Is truant from school (skips school) without permission 0 1 2 3 
31. Is physically cruel to people 0 1 2 3 
32. Has stolen things that have value 0 1 2 3 
33.  Deliberately destroys others’ property  0 1 2 3 
34. Has used a weapon that can cause serious harm (bat, knife, 
brick, gun) 
0 1 2 3 
35. Is physically cruel to animals 0 1 2 3 
36. Has deliberately set fires to cause damage 0 1 2 3 
37. Has broken into someone else’s home, business, or car 0 1 2 3 
38. Has stayed out at night without permission 0 1 2 3 
39. Has run away from home overnight 0 1 2 3 
40. Has forced someone into sexual activity 0 1 2 3 
41, Is fearful, anxious, or worried 0 1 2 3 
42. Is afraid to try new things for fear of making mistakes 0 1 2 3 
43. Feels worthless or inferior 0 1 2 3 
44. Blames self for problems, feels guilty 0 1 2 3 
45. Feels lonely, unwanted, or unloved; complains that “no one 
loves him or her 
0 1 2 3 
46. Is sad, unhappy, or depressed 0 1 2 3 
47. Is self-conscious or easily embarrassed 0 1 2 3 
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Performance 
E
x
c
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n
t 
A
b
o
v
e 
A
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e 
A
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P
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m
-
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48. Overall school performance 1 2 3 4 5 
49. Reading 1 2 3 4 5 
50. Writing 1 2 3 4 5 
51. Mathematics 1 2 3 4 5 
52. Relationship with parents 1 2 3 4 5 
53. Relationship with siblings 1 2 3 4 5 
54. Relationship with peers 1 2 3 4 5 
55. Participation in organized activities (e.g., teams) 1 2 3 4 5 
 Comments:      
 
 
TEACHER ASSESSMENT 
 Today’s Date: _________    Child’s Name:  _______________________ Teacher’s Name: 
_____________________ 
 
Directions: Each rating should be considered in the context of what is appropriate for the age 
of the child you are rating and should reflect that child’s behavior since the 
beginning of the school year. Please indicate the number of weeks or months you 
have been able to evaluate the behaviors: _________.    
Is this evaluation based on a time when the child: 
                                     was on medication     was not on medication      not sure? 
                   
  
Symptoms 
N
ev
er
 
O
cc
as
io
n
-
al
ly
 
O
ft
en
 
V
er
y
 
O
ft
en
 
1. Fails to give attention to details or 
makes careless mistakes in schoolwork 
0 1 2 3 
2. Has difficulty sustaining attention to tasks or 0 1 2 3 
 
For Office Use Only 
 
Total number of questions scored 2 or 3 in questions 1–9:                                                   
Total number of questions scored 2 or 3 in questions 10–18:                                             
Total Symptom Score for questions 1–18:                                                                                
Total number of questions scored 2 or 3 in questions 19–26:                                             
Total number of questions scored 2 or 3 in questions 27–40:                                             
Total number of questions scored 2 or 3 in questions 41–47:                                             
Total number of questions scored 4 or 5 in questions 48–55:     
Average Performance Score:    
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Symptoms 
N
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O
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V
er
y
 
O
ft
en
 
activities 
3. Does not seem to listen when spoken to directly 0 1 2 3 
4. Does not follow through on instructions and fails to 
finish schoolwork (not due to oppositional behavior 
or failure to understand) 
0 1 2 3 
5. Has difficulty organizing tasks and activities 0 1 2 3 
6. Avoids, dislikes, or is reluctant to engage in tasks 
that require sustained mental effort 
0 1 2 3 
7. Loses things necessary for tasks or activities 
(school assignments, pencils, or books) 
0 1 2 3 
8. Is easily distracted by extraneous stimuli 0 1 2 3 
9. Is forgetful in daily activities 0 1 2 3 
10. Fidgets with hands or feet or squirms in seat 0 1 2 3 
11. Leaves seat in classroom or in other situations in 
which remaining seated is expected 
0 1 2 3 
12. Runs about or climbs excessively in situations in 
which remaining seated is expected 
0 1 2 3 
13. Has difficulty playing or engaging in leisure activities 
quietly 
0 1 2 3 
14.  Is “on the go” or often acts as if “driven by a motor” 0 1 2 3 
15. Talks excessively 0 1 2 3 
16. Blurts out answers before questions have been 
completed 
0 1 2 3 
17. Has difficulty waiting in line 0 1 2 3 
18. Interrupts or intrudes on others (e.g., butts into 
conversations/games) 
0 1 2 3 
19. Loses temper 0 1 2 3 
20.  Actively defies or refuses to comply with adult’s 
requests or rules 
0 1 2 3 
21. Is angry or resentful 0 1 2 3 
22. Is spiteful and vindictive 0 1 2 3 
23. Bullies, threatens, or intimidates others 0 1 2 3 
24. Initiates physical fights 0 1 2 3 
25.  Lies to obtain goods for favors or to avoid obligations 
(e.g., “cons” others) 
0 1 2 3 
26. Is physically cruel to people 0 1 2 3 
27. Has stolen items of nontrivial value 0 1 2 3 
28.  Deliberately destroys others’ property 0 1 2 3 
29. Is fearful, anxious, or worried 0 1 2 3 
30. Is self-conscious or easily embarrassed 0 1 2 3 
31. Is afraid to try new things for fear of making mistakes 0 1 2 3 
32. Feels worthless or inferior                                                                         0 1 2 3 
33.  Blames self for problems; feels guilty                                                                0 1 2 3
34.  Feels lonely, unwanted, or unloved; complains that “no 
one loves him” 
0 1 2 3 
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Symptoms 
N
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35. Is sad, unhappy, or depressed 0 1 2 3 
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 Academic Performance      
36. Reading 1 2 3 4 5 
37. Mathematics 1 2 3 4 5 
38. Written expression 1 2 3 4 5 
  1 2 3 4 5 
 Classroom Behavioral Performance 1 2 3 4 5 
39. Relationship with peers 1 2 3 4 5 
40. Following directions 1 2 3 4 5 
41, Disrupting class 1 2 3 4 5 
42. Assignment completion 1 2 3 4 5 
43. Organizational skills 1 2 3 4 5 
 Comments: 
 
    
 
 
                  
 
 
  
 
 
Please return this form to:     Mailing address:     
 
 
Fax number:       
For Office Use Only 
Total number of questions scored 2 or 3 in questions 1–9:                                                    
Total  number of questions scored 2 or 3 in questions 10–18:                                               
Total Symptom Score for questions 1–18:                                                                                      
Total  number of questions scored 2 or 3 in questions 19–28:                                               
Total  number of questions scored 2 or 3 in questions 29–35:                                               
Total  number of questions scored 4 or 5 in questions 36–43:                                    
Average Performance Score:   
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APPENDIX D 
VANDERBILT FOLLOW-UP FORM – PARENT RESPONDENT 
 
Parent’s Name: __________________________________Parent’s phone number: ____________ 
 
Directions: Each rating should be considered in the context of what is appropriate for the age of 
your child. Please think about your child’s behaviors since the last assessment scale 
was filled out when rating his/her behaviors. 
This evaluation should be based on a time when the child was on medication. 
 
  
Symptoms 
N
ev
er
 
O
cc
as
io
n
-
al
ly
 
O
ft
en
 
V
er
y
 
O
ft
en
 
1. Does not pay attention to details or makes 
careless mistakes with, for example, homework 
0 1 2 3 
2. Has difficulty keeping attention to what needs to be done 0 1 2 3 
3. Does not seem to listen when spoken to directly 0 1 2 3 
4. Does not follow through when given directions and fails to 
finish activities (not due to refusal or failure to understand) 
0 1 2 3 
5. Has difficulty organizing tasks and activities 0 1 2 3 
6. Avoids, dislikes, or does not want to start tasks that 
require ongoing mental effort 
0 1 2 3 
7. Loses things necessary for tasks or activities (toys, 
assignments, pencils, or books) 
0 1 2 3 
8. Is easily distracted by noises or other stimuli 0 1 2 3 
9. Is forgetful in daily activities 0 1 2 3 
10. Fidgets with hands or feet or squirms in seat 0 1 2 3 
11. Leaves seat when remaining seated is expected 0 1 2 3 
12. Runs about or climbs too much when remaining seated is 
expected 
0 1 2 3 
13. Has difficulty playing or beginning quiet play activities 0 1 2 3 
14.  Is “on the go” or often acts as if “driven by a motor” 0 1 2 3 
15. Talks too much 0 1 2 3 
16. Blurts out answers before questions have been completed 0 1 2 3 
17. Has difficulty waiting his or her turn 0 1 2 3 
18.  Interrupts or intrudes in on others’ conversations and/or 
activities 
0 1 2 3 
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19. Overall school performance 1 2 3 4 5 
20. Reading 1 2 3 4 5 
21. Writing 1 2 3 4 5 
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22. Mathematics 1 2 3 4 5 
23. Relationship with parents 1 2 3 4 5 
24. Relationship with siblings 1 2 3 4 5 
25. Relationship with peers 1 2 3 4 5 
26. Participation in organized activities (e.g., teams) 1 2 3 4 5 
 Comments: 
 
    
 
 
 
 
The information contained in this publication should not be used as a  substitute for the medical care 
and advice of your pediatrician. There may be variations in treatment that your pediatrician may 
recommend based on individual facts and circumstances. 
 
Copyright ©2002 American Academy of Pediatrics and National Initiative for Children ’s Healthcare 
Quality. Adapted from the Vanderbilt Rating Scales developed by Mark L. Wolraich, MD. Revised - 
0303 
 
For Office Use Only 
Total Symptom Score for questions 1–18:                                                                      
Average Performance Score for questions 19–26:    
 59 
Child’s Name:  _________________________________ Parent’s Phone Number: ________________ 
 
Side Effects: Has your child experienced 
any of the following side effects or problems 
in the past week? 
Are these side effects currently a 
problem? 
None Mild Moderate Severe 
     
     
     
     
 
    
 
    
     
     
     
 
    
 
    
      e     
 
Total number of moderate or severe side effects:  ________ 
 
Explain/Comments: 
 
 
Adapted from the Pittsburgh side effects scale, developed by William E. Pelham, Jr, PhD  
 
These scales should NOT be used alone to make any diagnosis.  You must take into consideration  
information from multiple sources. Scores of 2 or 3 on a single Symptom question reflect  
often-occurring behaviors. Scores of 4 or 5 on Performance questions reflect problems in 
performance. 
 
The initial assessment scales, parent and teacher, have 2 components: symptom assessment and 
impairment in performance.  On both the parent and teacher initial scales, the symptom assessment 
screens for symptoms that meet criteria for both inattentive (items 1–9) and hyperactive ADHD 
(items 10–18). To meet DSM-IV criteria for the diagnosis, one must have at least 6 positive 
responses to either the inattentive 9 or hyperactive 9 core symptoms, or both. A positive response 
is a 2 or 3 (often, very often).  
 
The initial scales also have symptom screens for 3 other co- morbidities—oppositional-
defiant, conduct, and anxiety/depression. These are screened by the number of positive 
responses in each of the segments separated by the “squares.” The specific item sets and 
numbers of positives required for each co-morbid symptom screen set are detailed 
below. The second section of the scale has a set of performance measures, scored 1 to 5, 
with 4 and 5 being somewhat of a problem/problematic. To meet criteria for ADHD 
there must be at least one item of the Performance set in which the child scores a 4 or 5; 
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i.e., there must be impairment, not just symptoms to meet diagnostic criteria. The sheet 
has a place to record the number of positives (4s, 5s) and an Average Performance 
Score. 
 
 
Parent Assessment Scale Teacher Assessment Scale 
Predominantly Inattentive subtype 
■ Must score a 2 or 3 on 6 out of 9 it ems on questions 
1–9 AND 
■ Score a 4 or 5 on any of the Performance questions 
48–55 
Predominantly Hyperactive/Impulsive subtype 
■ Must score a 2 or 3 on 6 out of 9 items on 
questions 10–18 AND 
■ Score a 4 or 5 on any of the Performance questions 
48–55 
ADHD Combined Inattention/Hyperactivity 
■ Requires the above criteria on both 
inattention and 
hyperactivity/impulsivity 
Oppositional-Defiant Disorder Screen 
■ Must score a 2 or 3 on 4 out of 8 behaviors on 
questions 19–26 AND 
■ Score a 4 or 5 on any of the Performance questions 
48–55 
Conduct Disorder Screen 
■ Must score a 2 or 3 on 3 out of 14 behaviors 
on questions 27–40 AND 
■ Score a 4 or 5 on any of the Performance questions 
48–55 
Anxiety/Depression Screen 
■ Must score a 2 or 3 on 3 out of 7 behaviors on 
questions 41–47 AND 
■ Score a 4 or 5 on any of the Performance questions 
48–55 
Predominantly Inattentive subtype 
■ Must score a 2 or 3 on 6 out of 9 it ems on 
questions 1–9 AND 
■ Score a 4 or 5 on any of the Performance 
questions 36–43 
Predominantly Hyperactive/Impulsive subtype 
■ Must score a 2 or 3 on 6 out of 9 it ems on 
questions 10–18 AND 
■ Score a 4 or 5 on any of the Performance 
questions 36–43 
ADHD Combined Inattention/Hyperactivity 
■ Requires the above criteria on 
both inattention and 
hyperactivity/impulsivity 
Oppositional-Defiant/Conduct Disorder 
Screen 
■ Must score a 2 or 3 on 3 out of 10 items 
on questions 19–28 AND 
■ Score a 4 or 5 on any of the Performance 
questions 36–43 
Anxiety/Depression Screen 
■ Must score a 2 or 3 on 3 out of 7 items 
on questions 29–35 AND 
■ Score a 4 or 5 on any of the Performance 
questions 36–43 
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APPENDIX E 
KINDL Quality-of-Life Questionnaire 
 
 
 
 
 
 
 
 
 
Dear Parent, 
 
We really appreciate your taking the time to complete this questionnaire about your child’s 
well-being and health-related quality of life. 
Since it is a matter of your own assessment of your child’s well-being, please complete the 
questionnaire yourself according to the instructions, i.e. without asking your child. 
 
 Read each question carefully. 
 Think about how your child has been feeling during the past week. 
 Put a cross in the box corresponding to the answer in each line that fits your child best. 
 
For example: 
During the past week ...  
Never seldom 
some- 
times 
often 
all the 
time 
. ...my child has slept well      
 
 
 
My Child is a:  Girl  Boy  
Age:   Years   
You are:  Mother  Father  Other  ? 
Date of fill out:   /  /  (day / month / year) 
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1. Physical Well-being 
During the past week ... never seldom 
some- 
times 
often 
all 
the 
time 
1. … my child felt ill      
2. … my child had a headache or 
tummy- ache 
     
3. … my child was tired and worn-
out 
     
4. ... my child felt strong and full of 
energy 
     
 
 
2. Emotional Well-being 
 
During the past week ... never seldom 
some- 
times 
often 
all 
the 
time 
1. ... my child had fun and laughed a 
lot 
     
2. ... my child didn't feel much like 
doing anything 
     
3. ... my child felt alone      
4. ... my child felt scared or unsure 
of him-/ herself 
     
 
3. Self-esteem 
 
During the past week ... never seldom 
some- 
times 
often 
all 
the 
time 
1. ... my child was proud of him-
/herself 
     
2. ... my child felt on top of the 
world 
     
3. ... my child felt pleased with 
him-/ herself 
     
4. ... my child had lots of good 
ideas 
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4. Family 
During the past week ... never seldom 
some- 
times 
often 
all 
the 
time 
1. ... my child got on well 
with us as parents 
     
2. ... my child felt fine at home      
3. ... we quarreled at home      
4. ... my child felt that I was bossing 
him/ her around 
     
5. Social Contacts 
 
During the past week ... never seldom 
some- 
times 
often 
all 
the 
time 
1. 1
. 
... my child did things together 
with friends 
     
2. 2
. 
... my child was liked by other kids      
3. 3
. 
... my child got along well with 
his/ her friends 
     
4. 4
. 
... my child felt different from other 
children 
     
6. School 
During the last week in 
which my child was at 
school ... 
 
never 
 
seldom 
some- 
times 
 
often 
all the 
time 
1. ... my child easily coped with 
schoolwork 
     
2. ... my child enjoyed the school 
lessons 
     
3. ... my child worried about 
his/her future 
     
4. ... my child was afraid of bad 
marks or grades 
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PARENT ASSESSMENT Follow-up — Calculate Total Symptom Score for questions 1–18. 
Calculate Average Performance Score questions 19–26.   
 
TEACHER ASSESSMENT Follow-up — Calculate Total Symptom Score for questions 1–18.  
Calculate Average Performance Score for questions 19.  
 
The parent and teacher follow-up scales have the first 18 core ADHD symptoms, not the co-
morbid symptoms. The section segment has the same Performance items and impairment 
assessment as the initial scales, and then has a side-effect reporting scale that the average of the 
Performance items answered as measures of improvement over time with treatment. Parent 
Assessment Follow-up can be used to both assess and monitor the presence of adverse reactions 
to medications prescribed. 
 
  
 65  
APPENDIX F 
KINDL COLLABORATON LETTER 
 
Dear Rebecca Dragomani, 
 
Thank you for your interest in the KINDL instruments. 
 
We have now received your complete signed collaboration form and are very happy to collaborate with 
you.  
 
You should be able to find the questionnaires as well as the manual for the questionnaires (in English) on 
our website:  http://kindl.org/english/. 
 
For a better documentation on our side and to assure that requests regarding the KINDL are being dealt 
with as quickly as possible we do assign ID numbers to every request. 
 
In your case, it is number 1437. 
 
It would be very helpful for us if you could state this number every time you contact us. This becomes 
even more important if eventually some other person from your team needs to contact us. By knowing the 
number, we are than able to quickly connect people to the right projects and hopefully reply to requests 
even faster.  In case of any questions, please feel free to contact us again. 
  
With kind regards, 
  
Toni Maria Klein 
Office of Quality of Life Measures in Children | Wissenschaftliche Assistentin  
  
 
  
Universitätsklinikum Hamburg-Eppendorf 
Zentrum für Psychosoziale Medizin 
Klinik für Kinder- und Jugendpsychiatrie, -psychotherapie und -psychosomatik 
Forschungssektion “Child Public Health” 
  
Martinistraße 52, W 29 
20246 Hamburg 
Tel.: (040) 7410 -58503 
Fax: (040) 7410 55105 
Email: QOL@uke.de 
Info: http://www.child-public-health.org 
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